Topics

Epigenetic Reader Proteins Drive Tumor Heterogeneity

Tumor Microenvironment Cancer Immunotherapy DNA Metabolism And Repair

Epigenetic reader proteins drive tumor heterogeneity by interpreting chromatin marks and converting them into transcriptional programs that diversify cancer-cell states. Bromodomain-containing readers recognize acetylated lysines, BET proteins regulate gene expression, and epigenetic heterogeneity contributes to intratumor phenotypic and molecular variation, cancer progression, and drug resistance[1][2][3].

BET proteins, especially BRD4, connect acetylated chromatin to oncogenic transcription. BRD4 supports cancer stem-like programs through ΔNp63α in squamous cell carcinoma, cooperates with YAP to maintain ROR1-driven tumor-initiating cells in pancreatic cancer, and regulates PD-L1 expression in ovarian cancer models[4][5][6].

Disease applications center on targeted epigenetic therapy, cancer stemness, immune evasion, DNA-damage response, and combination treatment. BET inhibition has shown preclinical anticancer activity, but clinical studies report limited single-agent efficacy, supporting combination strategies such as BET plus PARP inhibition in BRCA-proficient ovarian cancer and BET inhibitors in selected solid tumors or hematologic malignancies[7][8][9][10].

Key gaps include incomplete biomarkers for reader-protein dependency, context-specific resistance mechanisms, toxicity from broad BET blockade, and limited clinical durability as monotherapy. Future work should prioritize selective reader inhibitors, BET degraders, tumor-state biomarkers, immune-combination studies, and single-cell epigenomic approaches that link chromatin-reader activity to tumor evolution and therapy resistance[3][7][8][10].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-10162 Olaparib
Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator. Olaparib cannot cross the intact blood-brain barrier (BBB).
PARP   Autophagy   Mitophagy  
Prostate Cancer   Gastric Cancer   Cervical Cancer   Pancreatic Cancer   Ovarian Cancer   Digestive System Inflammation   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer   Glioblastoma   Endometrial Cancer  
386
HY-10201 Sorafenib
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
Raf   VEGFR   FLT3   Autophagy   Apoptosis   STAT   Akt   MMP   Cadherin   p38 MAPK   ERK   MEK   PI3K   PARP   Bcl-2 Family   Ephrin Receptor   PDGFR  
Gastric Cancer   Liver Cancer   Ovarian Cancer   Digestive System Inflammation   Small Cell Lung Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   Metastatic Colorectal Cancer   Metastatic Prostate Cancer   Multiple Myeloma   Metastatic Pancreatic Cancer   SARS-CoV-2 Infection   Alzheimer's Disease   Parkinson's Disease   Obesity   Lung Fibrosis  
316
HY-13030 (+)-JQ-1
(+)-JQ-1 (JQ1), a chemical probe, is a potent, specific, CNS-penetrant and reversible BET bromodomain inhibitor, with IC50s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2)). (+)-JQ-1 also activates autophagy.
Epigenetic Reader Domain   Autophagy   Ligands for Target Protein for PROTAC   SWI/SNF Complex  
Neurological, Eye or Ear Disease   Leukemia/Lymphoma/Myeloma  
309
HY-50895 Gefitinib
Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
EGFR   Autophagy   Apoptosis  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Lipid Metabolism   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Metastatic Breast Cancer   SARS-CoV-2 Infection  
222
HY-15147 XAV-939
XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation.
β-catenin   PARP  
Neurological, Eye or Ear Disease   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Hypertension   Lung Fibrosis  
209
HY-15772 Osimertinib
Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
EGFR  
Lung Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Glucose Metabolism   SARS-CoV-2 Infection   Hepatitis C Virus Infection   Obesity  
208
HY-50896 Erlotinib
Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions.
EGFR   OAT   ERK   GSK-3   β-catenin  
Gastric Cancer   Pancreatic Cancer   Renal Disease   Non-Small Cell Lung Cancer   Lung Adenocarcinoma  
147
HY-B0141 Estradiol
Estradiol (β-Estradiol) is a steroid hormone and the major female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering.
Estrogen Receptor/ERR   Endogenous Metabolite   Bacterial  
Metabolic or Endocrine Disease   Prostate Cancer   Viral Infection   Bacterial Infection   Neurodegenerative Disease   Cardiovascular Disease   Luminal Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
141
HY-N0005 Curcumin
Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin is a photosensitizer against microorganisms. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.
Histone Acetyltransferase   Epigenetic Reader Domain   Keap1-Nrf2   Autophagy   Mitophagy   Influenza Virus   Ferroptosis   Apoptosis  
Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Viral Infection   Pain   Digestive System Inflammation   Glucose Metabolism   Metastatic Breast Cancer   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
138
HY-L001P Bioactive Compound Library Plus
Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype. MCE owns a unique collection of 32,925 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. This library is a useful tool for signal pathway research, drug discovery and drug repurposing, etc. Bioactive Compound Library Plus, with more powerful screening capability, further complements Bioactive Compound Library (HY-L001) by adding some compounds with low solubility or solution stability (Part B) and some novel, rare or exclusive compounds (Part C) to this library. Overall, bioactive compound library plus (HY-L001P) includes tree parts: Part A, Part B and Part C. Compounds in Part A are equal to the products in HY-L001, which can be supplied in solution or solid form. Compounds in Part B and C are only supplied in solid form.

General Bioactive Screening Libraries

131
HY-107455 A-485
A-485, a chemical probe, is a potent and selective catalytic inhibitor of p300/CBP with IC50s of 9.8 nM and 2.6 nM for p300 and CBP histone acetyltransferase (HAT), respectively.
Epigenetic Reader Domain   Histone Acetyltransferase  
Leukemia/Lymphoma/Myeloma   Lung Fibrosis  
114
HY-10261 Afatinib
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.
EGFR   Autophagy   Apoptosis   c-Met/HGFR   Akt   p38 MAPK  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Hepatitis C Virus Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
113
HY-16106 Talazoparib
Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity.
PARP  
Breast Cancer   Prostate Cancer   Pancreatic Cancer   Ovarian Cancer   SARS-CoV-2 Infection  
112
HY-50898 Lapatinib
Lapatinib (GW572016) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
EGFR   Autophagy   Ferroptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   HER-2 Positive Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Hepatitis C Virus Infection   Obesity  
100
HY-L025 Anti-Cancer Compound Library
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Disease Focused Libraries

100
HY-13823 C646
C646 is a selective and competitive histone acetyltransferase p300 inhibitor with Ki of 400 nM, and is less potent for other acetyltransferases.
Histone Acetyltransferase   Autophagy   Epigenetic Reader Domain   Apoptosis  
Digestive System Disease   Leukemia/Lymphoma/Myeloma   Digestive System Inflammation   Glucose Metabolism  
98
HY-B0673 Pirfenidone
Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities.
TGF-beta/Smad   CCR  
Colorectal Cancer   Prostate Cancer   Viral Infection   Digestive System Inflammation   SARS-CoV-2 Infection   Lung Fibrosis   Rheumatoid Arthritis  
96
HY-14596 Genistein
Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.
EGFR   Autophagy   Apoptosis   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Lung Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Digestive System Inflammation   SARS-CoV-2 Infection   Hepatitis C Virus Infection   Obesity  
94
HY-10619 Niraparib
Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.
PARP   Apoptosis  
Breast Cancer   Prostate Cancer   Pancreatic Cancer   Ovarian Cancer   Digestive System Inflammation   SARS-CoV-2 Infection  
89
HY-L007 Immunology/Inflammation Compound Library
The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation. MCE designs a unique collection of 8,643 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

Signaling Pathway Targeting Libraries

89
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L048 Antifungal Compound Library
The high rates of morbidity and mortality caused by fungal infections are associated with the current limited antifungal arsenal and the high toxicity of the compounds. Additionally, identifying novel drug targets is challenging because there are many similarities between fungal and human cells. The most common antifungal targets include fungal RNA synthesis and cell wall and membrane components, though new antifungal targets are being investigated. Nonetheless, fungi have developed resistance mechanisms, such as overexpression of efflux pump proteins, overexpression and changes in drug targets and biofilm formation, emphasizing the importance of discovering new antifungal drugs and therapies. Due to the limited antifungal arsenal, researchers have sought to improve treatment via different approaches, such as the combination of antifungal drugs, development of new formulations for antifungal agents and modifications to the chemical structures of traditional antifungals, etc. MCE offers a unique collection of 585 compounds with validated antifungal activities. MCE antifungal compound library is an effective tool for drug repurposing screening, combination screening and biological investigation.

Disease Focused Libraries

87
HY-L017 Stem Cell Signaling Compound Library
Adult stem cells are important for tissue homeostasis and regeneration due to their ability to self-renew and generate multiple types of differentiated daughters. Self-renewal is reflected by their capacity to undergo multiple/limitless divisions. Several signaling pathways are involved in self-renewal of stem cells, that is, Notch, Wnt, and Hedgehog pathways or Polycomb family proteins. Recent studies mainly focus on cancer stem cell (CSCs), induced pluripotent stem cell (iPSCs), neural stem cell and maintenance of embryonic stem cell pluripotency. Among them, CSCs have been believed to be responsible for tumor initiation, growth, and recurrence that have implications for cancer therapy. MCE owns a unique collection of 2,931 compounds that can be used for stem cell regulatory and signaling pathway research.

Signaling Pathway Targeting Libraries

86
HY-L020 Wnt/Hedgehog/Notch Compound Library
The developmental proteins Hedgehog, Notch and Wnt are key regulators of cell fate, proliferation, migration and differentiation in several tissues. Their related signaling pathways are frequently activated in tumors, and particularly in the rare subpopulation of cancer stem cells. The Wnt signaling pathway is a conserved pathway in animals. Deregulated Wnt signaling has catastrophic consequences for the developing embryo and it is now well appreciated that defective Wnt signaling is a causative factor for a number of pleiotropic human pathologies, including cancer. Hedgehog signaling pathway is linked to tumorigenesis and is aberrantly activated in a variety of cancers. The Notch signaling pathway is a highly conserved cell signaling system present in most animals. It plays an important role in cell-cell communication, and further regulates embryonic development. MCE designs a unique collection of 654 Wnt/Hedgehog/Notch signaling pathway-related small molecules. Wnt/Hedgehog/Notch Compound Library serves as a useful tool for stem cell research and anti-cancer drug screening.

Signaling Pathway Targeting Libraries

86
HY-L109 Protein-protein Interaction Inhibitor Library
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures. With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 826 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Signaling Pathway Targeting Libraries

86
HY-L024 Histone Modification Research Compound Library
A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases. MCE owns a unique collection of 931 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Signaling Pathway Targeting Libraries

85
HY-L040 Anti-diabetic Compound Library
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage. The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes. MCE Anti-diabetic Compound Library owns a unique collection of 1,172 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Disease Focused Libraries

84
HY-L075 Anti-Lung Cancer Compound Library
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Disease Focused Libraries

84
HY-L080 Targeted Therapy Drug Library
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer. There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases. MCE carefully collects a unique of 106 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

Disease Focused Libraries

84
HY-L151 PROTAC Library
PROTACs (Proteolysis-targeting chimeras) is a class of molecules that utilize ubiquitin-proteasome system (UPS) to ubiquitinate and degrade target proteins. The PROTACs molecule consists of two ligands joined by a linker. The one-to-one interaction between PROTACs and target proteins determines the high efficiency of PROTACs, making it a potential molecule for targeted protein degradation (TPD) therapy. MCE supplies a unique collection of 544 PROTACs that effectively degrade target proteins with more powerful screening capability. MCE PROTAC Library is a useful tool for signal pathway research, protein degradation therapy research, drug discovery and drug repurposing, etc.

Compound Characteristic Classified Libraries

84
HY-L188 Anti-Brain Cancer Compound Library
Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets. MCE designs a unique collection of 2,134 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.
84
HY-L079 Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L129 Target Protein Ligand Library
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance. MCE carefully prepared a unique collection of 128 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

Compound Characteristic Classified Libraries

83
HY-L135 Cancer Stem Cells Compound Library
With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on. Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment. MCE supplies a unique collection of 3,540 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.

Compound Characteristic Classified Libraries

83
HY-L169 Anti-Drug-Resistant Compound Library
Resistance refers to the decrease in the effectiveness of drugs in treating diseases or symptoms. Due to the increasing global antibiotic resistance, it may threaten our ability to treat common infectious diseases. Drug resistance is also the main cause of chemotherapy failure in malignant tumors. In approximately 50% of cases, drug resistance exists even before chemotherapy begins. There are many mechanisms of anticancer drug resistance, including increased protein expression that leads to drug removal, mutations in drug binding sites, recovery of tumor protein production, and pre-existing genetic heterogeneity in tumor cell populations. In addition, the issue of drug resistance seems to have affected the development of new anticancer drugs. Drug resistance may be caused by various conditions, such as mutations, epigenetic modifications, and upregulation of drug efflux protein expression. Overcoming multidrug resistance in cancer treatment is becoming increasingly important. MCE designs a unique collection of 706 anti-drug-resistant compounds. It is a good tool to be used for research on cancer and other diseases.

Compound Characteristic Classified Libraries

83
HY-L171 Anti-Hematopathy Compound Library
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 4,388 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Disease Focused Libraries

83
HY-L173 Anti-Ovarian Cancer Compound Library
Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer. MCE designs a unique collection of 2,967 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Disease Focused Libraries

83
HY-L176 Multi-Target Compound Library
The occurrence of diseases is often associated with multiple targets and pathways, and the factors of disease formation are complex and diverse, so the development of more powerful drugs is needed. According to statistics, 21% of the FDA-approved drugs in 2015-2017 were multi-target compounds. Multi-target compounds refer to a drug targeting multiple disease-related targets or multiple subtypes of a target. Multi-target compounds can be applied to drug screening or targeted ligand design. Because the targets of such compounds are diverse and clear, they have the characteristics of saving time and drug cost during the mechanism research of new drug research and development. In addition, due to the diversity of drug targets, multiple strategies can be applied to pharmacological studies. MCE supplies a unique collection of 7,362 multi-target compounds that targets two or more different targets or different subtypes of the same target. MCE Multi-Target Compound Library can be used for target protein ligand screening or drug development.

General Bioactive Screening Libraries

83
HY-L177 Antibody Inhibitor Library
Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases. MCE can provide 1,949 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.

Compound Characteristic Classified Libraries

83
HY-L178 Radioprotector Library
Radiation sickness is a general term for various types and degrees of damage (or disease) occurring in the human body after exposure to ionizing radiation. Although small amounts of ionizing radiation can also cause the body to produce free radicals and ROS, causing oxidative stress, resulting in DNA damage and chromosomal aberration. Radioprotector are compounds with radiation protection that can be used to prevent/protect non-tumor cells from the harmful effects of radiation. Radioprotective compounds can prevent the damage of radioactive substances to the human body and reduce the clinical symptoms of various radioactive diseases. In addition, radioprotectors can protect normal cells from damage during radiation therapy. The ideal anti-radiation drug should not affect the sensitivity of tumor cells to radiation therapy while protecting normal cells. MCE designs a unique collection of 3,066 radioprotectors. Radioprotector Library is an effective tool for acute Radiation Syndrome, drug combination research with radiation drugs.

Compound Characteristic Classified Libraries

83
HY-L179 Radiosensitizer Library
Radiotherapy is a common treatment for various cancers, and more than 50% of cancer patients require radiotherapy during the disease treatment. With advances in radiation technology and a better understanding of tumor biology, the efficacy of radiation therapy has gradually improved, and more and more patients have benefited from it. However, even with the use of advanced radiotherapy techniques, there are still many malignant tumor cells with low sensitivity to radiation, leading to the radiation effect is not ideal. To solve this problem, radiosensitizers have received more and more attention. Radiosensitizer is a kind of drug that can enhance the radiosensitivity of tumor cells and improve the effect of radiotherapy. Radiation sensitizers act in a variety of ways, such as killing hypoxic cells, enhancing DNA damage, inhibiting DNA damage repair, and blocking cell cycle progression, making tumor cells more susceptible to radiation damage and death than surrounding normal cells. MCE designs a unique collection of 39 compounds with definite reported radiosensitization. It can be used for drug combination research in anti-cancer treatment.

Compound Characteristic Classified Libraries

83
HY-L184 Anti-Gastric Cancer Compound Library
Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer. MCE designs a unique collection of 1,203 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

Disease Focused Libraries

83
HY-L228 Lipid Metabolite Compound Library
Lipids are important energy storage substances in the human body. They are involved in the regulation of cell structure and function, as well as signaling pathways and gene expression. Abnormal lipid levels in tissues or their dysregulation can lead to various diseases. These include obesity, type 2 diabetes, non-alcoholic fatty liver disease, neurodegenerative diseases, infections, and cancer. Therefore, maintaining normal levels of lipid metabolism is critical to overall health. One of the key features of cancer is aberrant lipid metabolism. This includes alterations in lipid uptake, lipid desaturation, neolipogenesis, lipid droplets, and fatty acid oxidation in cancer cells. These changes all contribute to cellular survival in an ever-changing microenvironment. They do this by modulating feed-forward oncogenic signals and key oncogenic functions. Additionally, they affect oxidative stress, other types of stress, immune responses, and intercellular communication. Alterations in lipid metabolism have a strong impact on the properties of cancer stem cells. This includes aspects such as self-renewal, differentiation, invasion, metastasis, drug sensitivity, and resistance. Furthermore, these alterations also modulate T cell responses. MCE can offer 146 metabolites of lipid metabolism pathways, which can be used for drug screening in cancer, immune-based diseases, metabolic diseases, and other diseases.

Metabolism Focused Libraries

83
HY-L244 High-Efficiency Gene Editing Compound Library
In this era of rapid advancement in gene-editing technology, the CRISPR-Cas system, with its powerful programmability, is leading a transformation in life sciences research. It enables efficient and precise targeted modification of an organism's genome, providing a robust tool for studying gene function, treating genetic diseases, and improving crop varieties. However, bottlenecks such as insufficient editing efficiency, low homologous directed repair efficiency, and potential off-target risks remain major challenges in achieving precise genetic modifications and developing gene therapies. To overcome these limitations, the MCE High-Efficiency Gene Editing Compound Library systematically includes 761 small molecules that are known or have the potential to enhance gene-editing efficiency. These compounds work by targeting and modulating the DNA damage repair network, mechanistically inhibiting non-homologous end joining, promoting homologous directed repair, or regulating chromatin states and cellular responses, thereby significantly optimizing editing outcomes. This library is suitable for developing "CRISPR-small molecule" combination therapy strategies, improving gene-editing efficiency, and providing a powerful tool for in-depth research into the mechanisms of DNA damage repair in gene editing.

Signaling Pathway Targeting Libraries

83
HY-L261 Classic FDA-Approved Drug Library
MCE Classic FDA-Approved Drug Library features a curated selection of marketed drugs that have achieved the highest prescription volumes and greatest clinical impact in global practice since 2006. The collection covers eight major therapeutic areas, including cardiovascular diseases, oncology, metabolic disorders, infectious diseases, central nervous system disorders, respiratory diseases, digestive system diseases, and immunological conditions. All compounds have been validated through long‑term clinical use and possess well‑defined molecular targets, well‑established pharmacokinetic properties, quantifiable efficacy endpoints, and comprehensive toxicological safety profiles. The library currently contains 167 representative drugs and is designed to serve as an efficient tool for drug repurposing, phenotypic screening, mechanism‑of‑action studies, and combination therapy strategy development.

Drug Repurposing Series

83
HY-L948 PD-1/PD-L1 Lead-like Library
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy. A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity. Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.

Focused and target libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-P9907 Trastuzumab
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)

Species: Human

Radionuclide-Drug Conjugates (RDCs)   EGFR   ADC Antibodies  
Non-Small Cell Lung Cancer   Luminal Breast Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
71
HY-101120 666-15
666-15 is a potent and selective CREB inhibitor with an IC50 of 81 nM. 666-15 suppresses tumor growth in a breast cancer xenograft model.
Epigenetic Reader Domain  
Breast Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pain   Obesity  
65
HY-50698 BI 2536
BI 2536 is a dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription.
Polo-like Kinase (PLK)   Epigenetic Reader Domain   Apoptosis  
Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Digestive System Inflammation  
61
HY-134653 5-Ph-IAA
5-Ph-IAA is a derivative of IAA. 5-Ph-IAA, a ligand, establishes the auxin-inducible degron 2 (AID2) system together with an OsTIR1 (F74G) mutant. AID2 induces rapid and efficient depletion of mAID-fused proteins to study protein function in living cells, causing tumor suppression.
Epigenetic Reader Domain  
Leukemia/Lymphoma/Myeloma  
61
HY-13004 Maraviroc
Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV.
CCR   HIV  
Metabolic or Endocrine Disease   Pancreatic Cancer   Viral Infection   Digestive System Inflammation   SARS-CoV-2 Infection   Lung Fibrosis   Rheumatoid Arthritis  
60
HY-P9905 Cetuximab
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.

Species: Human

Radionuclide-Drug Conjugates (RDCs)   EGFR  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
57
HY-10617A Rucaparib
Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research.
PARP  
52
HY-K0030 Deacetylase Inhibitor Cocktail (100× in 70% DMSO)

MCE Deacetylase Inhibitor Cocktail is a synergistic combination of chemicals designed to preserve the acetylation state of proteins.The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

Protein Biology Protein Sample Preparation Deacetylase Inhibitor Cocktail

45
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-15418 RS 504393
RS 504393 is a selective CCR2 chemokine receptor antagonist (IC50 values are 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors respectively).
CCR  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
33
HY-50674 INCB3344
INCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.
CCR  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
30
HY-B0498 Bindarit
Bindarit (AF2838) is a selective inhibitor of the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8, and no effect on other CC and CXC chemokines such as MIP-1α/CCL3, MIP-1β/CCL4, MIP-3/CCL23. Bindarit also has anti-inflammatory activity.
CCR  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   SARS-CoV-2 Infection   Lung Fibrosis   Rheumatoid Arthritis  
29
HY-12080 BX471
BX471 (ZK-811752) is an orally active, potent and selective non-peptide CCR1 antagonist with a Ki of 1 nM, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.
CCR  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
29
HY-18611A Abaucin
RS102895 is a potent CCR2 antagonist, with an IC50 of 360 nM, and shows no effect on CCR1.
CCR  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
28
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-N0171A Beta-Sitosterol (purity>98%)
Beta-Sitosterol (purity>98%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc.
Bacterial   Apoptosis   Reactive Oxygen Species (ROS)   MDM-2/p53   Caspase   PARP   MMP   Bcl-2 Family   HIF/HIF Prolyl-Hydroxylase   TNF Receptor   Interleukin Related   NF-κB   mTOR   Lactate Dehydrogenase   CDK   Glutathione Peroxidase   SOD  
Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Bacterial Infection   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
24
HY-132167 Saruparib
Saruparib (AZD5305) is a potent, orally active and selective PARP inhibitor and trapper with IC50 values of 3 nM and 1400 nM for PARP1 and PARP2, respectively. Saruparib has anti-proliferative activity and inhibits growth in cells with deficiencies in DNA repair.
PARP  
Breast Cancer   Prostate Cancer   Pancreatic Cancer   Ovarian Cancer  
24
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-N0140 Ursolic acid
Ursolic acid (Prunol) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.
Autophagy   Endogenous Metabolite  
Prostate Cancer   Leukemia/Lymphoma/Myeloma  
21
HY-13594 Chlorin e6
Chlorin e6 is a photosensitizer and has strong absorption peaks at wavelength of 402 and 662 nm, as well as exhibiting intense fluorescence at 668 nm. Chlorin e6 has antimicrobial efficacy and anticancer activity. Chlorin e6 induces cell apoptosis via caspase-3 activation and can be used for the research of cancer.
MOFs   Bcl-2 Family   Caspase   PARP   Apoptosis   Fluorescent Dye  
Cancer   Infection  
20
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-16900 Rolipram
Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis.
Bacterial   HIV   Phosphodiesterase (PDE)   Epigenetic Reader Domain   Amyloid-β  
Colorectal Cancer   Bacterial Infection   Depression   SARS-CoV-2 Infection   Alzheimer's Disease   Huntington's Disease   HIV-1 Infection  
19
HY-156498 RMC-7977
RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (Kd = 195 nM) and KRAS (G12V) (Kd = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRASG12C cancer models, and demonstrates good tolerability across various RAS cancer models.
Ras   ERK   Raf   Ribosomal S6 Kinase (RSK)   AMPK   Apoptosis   PARP  
18
HY-136175 Revumenib
Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
Epigenetic Reader Domain  
Leukemia/Lymphoma/Myeloma  
17
HY-K0315 Hematoxylin-Eosin Staining Kit

MCE Hematoxylin-Eosin Staining Kit can be used for cell staining, the combination of hematoxylin and eosin results in a staining pattern where the cytoplasm appears red or pink and the nucleus takes on a blue or blue-violet.

Cell Biology Cell Analysis Staining Kit

15
HY-13406 TAK-779
TAK-779 is a potent and selective nonpeptide antagonist of CCR5 and CXCR3, with a Ki of 1.1 nM for CCR5, and effectively and selectively inhibits R5 HIV-1, with EC50 and EC90 of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells.
CCR   HIV   CXCR  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Viral Infection   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
13
HY-111784 Inobrodib
Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with Kd values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a Kd of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression.
Ligands for Target Protein for PROTAC   Epigenetic Reader Domain   Histone Acetyltransferase  
Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   Metastatic Prostate Cancer  
13
HY-138298 Trastuzumab deruxtecan (solution)
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
Antibody-Drug Conjugates (ADCs)   EGFR  
Breast Cancer   Gastric Cancer  
12
HY-138298A Trastuzumab deruxtecan
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
Antibody-Drug Conjugates (ADCs)   EGFR  
Breast Cancer  
12
HY-108730A Avelumab (anti-PD-L1)
Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma.

Species: Human

PD-1/PD-L1  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Luminal Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
11
HY-108730 Avelumab
Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma.

Species: Human

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
11
HY-P73361 PD-L1 Protein, Human (HEK293)
The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (HEK293) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with tag free.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Epithelial cell CD Proteins PD-L1

10
HY-B2156 Menaquinone-4
Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.
Endogenous Metabolite  
Cancer  
8
HY-P74652 PARP1 Protein, Human (sf9, His)
The PARP1 protein is a polyADP-ribosyltransferase that crucially mediates polyADP-ribosylation (PARsylation) in DNA repair, including base excision and double-strand breaks. By interacting with factors such as HPF1 and NMNAT1, the specificity of PARP1 extends to various amino acids. PARP1 Protein, Human (sf9, His) is the recombinant human-derived PARP1 protein, expressed by Sf9 insect cells , with C-His labeled tag.

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Transferases (EC 2)

8
HY-P9919A Durvalumab (anti-PD-L1)
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity.

Species: Human

PD-1/PD-L1  
Colorectal Cancer   Liver Cancer   Bladder Cancer   Small Cell Lung Cancer   Lung Adenocarcinoma   Luminal Breast Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer   Multiple Myeloma   Pancreatic Ductal Adenocarcinoma   Metastatic Pancreatic Cancer  
7
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-N0596 Panaxadiol
Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities.
PD-1/PD-L1   HIF/HIF Prolyl-Hydroxylase   STAT  
Inflammation or Immune System Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Obesity  
4
HY-N0242 Fraxinellone
Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1.
PD-1/PD-L1   HIF/HIF Prolyl-Hydroxylase   STAT  
Inflammation or Immune System Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Obesity  
4
HY-151435 CCR6 antagonist 1
CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).
CCR  
Cancer   Digestive System Disease   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
4
HY-P7846 BRD4 Protein, Human (His-Flag)
The BRD4 protein is a chromatin reader that recognizes and binds acetylated histones, transmits epigenetic memory and regulates transcription during cell division. It associates with acetylated chromatin throughout the cell cycle, maintaining chromatin structure and contributing to epigenetic memory. BRD4 Protein, Human (His-Flag) is the recombinant human-derived BRD4 protein, expressed by E. coli , with N-10*His, N-Flag labeled tag.

Species: Human; Source: E. coli

4
HY-N4087 Platycodin D2
Platycodin D2 is an orally active triterpenoid saponin found in Platycodon grandiflorum. Platycodin D2 induces mitophagy in cancer cells through NIX, thereby activating the P21/CyclinA2 pathway and promoting cell senescence. Platycodin D2 induces mitochondrial dysfunction, enhances autophagy, inhibits hepatocellular carcinoma cell proliferation, and exhibits anti-tumor activity against multiple cancer cell types. Platycodin D2 promotes mRNA expression of T-bet, GATA-3, Th1 cytokines IL-2 and IFN-γ, and Th2 cytokines IL-4 and IL-10, enhances splenocyte proliferation, and acts as a vaccine adjuvant with low rabbit red blood cell hemolytic activity. Platycodin D2 induces mitochondrial ROS production, incomplete autophagy, and ferroptosis to inhibit breast cancer cell proliferation. Platycodin D2 can be used for the research of cancer, inflammation and immunology.
Mitophagy   Autophagy   Ferroptosis   Interleukin Related   IFNAR   Reactive Oxygen Species (ROS)  
Cancer   Inflammation or Immune System Disease  
3
HY-119347 Cirsilineol
Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4+ T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice.
IFNAR   STAT  
Cancer   Inflammation or Immune System Disease  
3
HY-P80448 Cleaved-PARP1 Antibody (YA500)
Cleaved-PARP1 Antibody (YA500) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cleaved-PARP1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

3
HY-P80263 PARP1 Antibody (YA246)
PARP1 Antibody (YA246) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PARP1.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

3
HY-N2000 Bellidifolin
Bellidifolin is an orally active compound with antiproliferative, anti-inflammatory and antioxidant properties. Bellidifolin modulates key signaling pathways including STAT3, PI3K-Akt, mTOR and BRD4, and inhibits the viral protein R (Vpr). Bellidifolin induces cell cycle arrest and apoptosis, exerts significant antifibrotic effects, and protects the heart, liver and nervous system. Bellidifolin is applicable to the research of various diseases such as lung cancer, non-alcoholic fatty liver disease, myocardial hypertrophy and ischemic cranial nerve injury.
STAT   PI3K   mTOR   Akt  
Digestive System Disease   Lung Cancer   Digestive System Inflammation   Ischemia-Reperfusion Injury  
2
HY-P1682 Balixafortide
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects.
CXCR   Arrestin  
2
HY-P1682A Balixafortide TFA
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects.
CXCR   Arrestin  
2
HY-N6647 Luteolin-7-rutinoside
Luteolin-7-rutinoside has both anti-arthritic and antifungal activities, can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection.
Fungal  
Inflammation or Immune System Disease   Fungal Infection   Lung Fibrosis  
2
HY-P990173 Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1)
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived PD-L1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer.

Species: Human/Mouse/Rat

PD-1/PD-L1  
Cancer  
2
HY-P99201 Zilovertamab
Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling.

Species: Human

ROR   Wnt  
Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
2
HY-P80976 BRD4 Antibody (YA3486)
BRD4 Antibody (YA3486) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRD4.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

2
HY-123298 Chrysotoxine
Chrysotoxine is a dual inhibitor of Src/Akt. Chrysotoxine suppresses cancer stem cells (CSCs) phenotypes by down-regulating Src/Akt signaling. Chrysotoxine reduces cell viability and increases apoptosis level in H460 and H23 cells instead of non-tumor cell lines. Chrysotoxine shows rapid excretion and low bioavailability in rats. Chrysotoxine is used in cancer research.
Src   Akt   Apoptosis  
1
HY-P990114 Anti-Canine PD-L1/B7-H1 Antibody (JC071)
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine PD-L1/B7-H1 IgG1 monoclonal antibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments.

Species: Canine

PD-1/PD-L1  
1
HY-P99604 Cilgavimab
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection.

Species: Virus

SARS-CoV  
SARS-CoV-2 Infection  
1
HY-15108G Purmorphamine (GMP)
Purmorphamine (GMP) is Purmorphamine (HY-15108) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Purmorphamine is a smoothened/Smo receptor agonist with an EC50 of 1 μM.
Smo  
Cancer   Neurological, Eye or Ear Disease  
1
HY-N3005 Britannin
Britannin is an NLRP3 inhibitor with an IC50 of 3.630 μM, exhibiting anti-inflammatory activity. Britannin inhibits the activation and assembly of the NLRP3 inflammasome by blocking the interaction between NLRP3 and NEK7. Additionally, Britannin demonstrates antitumor activity by inhibiting the proliferation of tumor cells through blocking the interaction between HIF-1α and Myc, thereby suppressing PD-L1 expression and enhancing cytotoxic T lymphocyte activity. Britannin can also induce apoptosis and autophagy in liver cancer cells by activating ROS-regulated AMPK. Britannin holds promise for research in the fields of anti-inflammatory and antitumor therapeutics.
Apoptosis   Autophagy   NOD-like Receptor (NLR)   Pyroptosis  
Prostate Cancer   Liver Cancer   Depression   Autoimmune Disease   Digestive System Inflammation  
1
HY-121608 Lumiflavin
Lumiflavin (Lumiflavine), a riboflavine analog, causes significant inhibition of riboflavine uptake. Lumiflavin can effectively reduce the riboflavin enrichment in cancer stem-like cells (CSCs) and sensitize the effect of cisplatin Diamminedichloroplatinum (DDP) on CSCs. Lumiflavin is promising for research of ovarian cancer.
Fluorescent Dye   Notch  
1
HY-P3719 MOG(35-55) amide, mouse, rat
MOG (35-55) amide, mouse, rat the terminal amidation form of the 35-55 fragment of the myelin oligodendrocyte glycoprotein (MOG) immunogenic peptide (MOG (35-55) (HY-P1240)). MOG(35-55) amide, mouse, rat can be used for experimental autoimmune encephalomyelitis (EAE) modeling.
CCR  
Inflammation or Immune System Disease  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P84982 PD-L1 Antibody (YA4674)
PD-L1 Antibody (YA4674) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

1
HY-KD1002 Vari Fluor 3-colour Multiple Fluorescent Staining Kit (For all samples)

The MCE three-color immunohistochemical kit marks the dual indicators. The kit contains a universal secondary antibody for mice and rats and can be used in combination with rabbit or mouse primary antibodies.

Protein Biology

1
HY-103048 PD-1/PD-L1-IN 3
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases.
PD-1/PD-L1  
/
HY-N0565AS Doxycycline-d3 (hydrochloride)
Doxycycline-d3 hydrochloride is deuterium labeled Doxycycline hydrochloride (HY-N0565A). Doxycycline hydrochloride is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline hydrochloride is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline hydrochloride also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline hydrochloride induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline hydrochloride also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline hydrochloride has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
Isotope-Labeled Compounds   MMP   Parasite   Bacterial   Antibiotic   Apoptosis   Akt   PI3K  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Bacterial Infection  
/
HY-N0565S3 Doxycycline-13C,d3
Doxycycline-13C,d3 is 13C and deuterium labeled Doxycycline (HY-N0565). Doxycycline is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
Isotope-Labeled Compounds   MMP   Parasite   Bacterial   Antibiotic   Apoptosis   Akt   PI3K  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Bacterial Infection  
/
HY-DP99144F1 Anti-Mouse PD-1 Antibody (RMP1-14), CY7 labeled
Anti-Mouse PD-1 Antibody (RMP1-14), CY7 labeled, is an Anti-Mouse PD-1 Antibody (RMP1-14) (HY-P99144) derivative carrying dye CY7 (HY-D0825). Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.
PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-N0596R Panaxadiol (Standard)
Panaxadiol (Standard) is the analytical standard of Panaxadiol. This product is intended for research and analytical applications. Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities.
Reference Standards   PD-1/PD-L1   HIF/HIF Prolyl-Hydroxylase   STAT  
Cancer  
/
HY-16397AS Phenformin-d5 hydrochloride
Phenformin-d5 (Phenethylbiguanide-d5) hydrochloride is the deuterium labeled Phenformin hydrochloride. Phenformin hydrochloride is an orally active biguanide hypoglycemic agent. Phenformin hydrochloride inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the mTOR pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin hydrochloride inhibits cancer stem cells (CSCs) and possesses potent antitumor potential.
Isotope-Labeled Compounds   Autophagy   mTOR   AMPK   Apoptosis   Mitochondrial Metabolism  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-13990G NVP-TNKS656 (GMP)
NVP-TNKS656 (GMP) is NVP-TNKS656 (HY-13990) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.
PPAR   Apoptosis  
/
HY-P99723 Manelimab
Manelimab (BCD-135) is a monoclonal antibody targeting PD-L1 with PD-L1 inhibitory activity. Manelimab blocks the interaction between PD-L1 and PD-1 to abrogate the immunosuppressive signals of T cells in the tumor microenvironment. Manelimab is applicable for tumor-related research.

Species: Human

PD-1/PD-L1  
Cancer  
/
HY-50698G BI 2536 (GMP)
BI 2536 (GMP) is BI 2536 (HY-50698) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BI 2536 is a dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription.
Polo-like Kinase (PLK)   Epigenetic Reader Domain   Apoptosis  
/
HY-P10445 TAT-PiET
TAT-PiET is a cell-penetrating peptide targeting the extra-terminal (ET) domain of BRD4. TAT-PiET can reduce BRD4 and JMJD6 levels and inhibit cell proliferation. TAT-PiET also resists the endocrine resistance of ERα-positive breast cancer cells. TAT-PiET can be used for the research of cancer, such as breast cancer.
Epigenetic Reader Domain  
/
HY-B0520AS1 Benztropine-d3 mesylate
Benztropine-d3 (mesylate) is the deuterium labeled Benztropine mesylate. Benztropine mesylate (Benzatropine mesylate) is an orally active centrally acting anticholinergic agent that can be used for Parkinson's disease research. Benztropine mesylate is an anti-histamine agent and a dopamine re-uptake inhibitor. Benztropine mesylate is also a human D2 dopamine receptor allosteric antagonist. Benztropine mesylate also has anti-CSCs (cancer stem cells) effects.
Dopamine Receptor   Histamine Receptor   mAChR  
Cancer  
/
HY-P4088 LyP-2
LyP-2 is a peptide that homes to tumor lymphatics. LyP2 homes to lymphatics of C8161 melanomas and cervical carcinomas and K14-HPV16 skin, but not to MDA-MB435 tumors, showing heterogeneity in the molecular markers of tumor cells and lymphatics.
Others  
Cancer  
/
HY-P10433 EGFRvIII peptide
EGFRvIII peptide is an EGFRvIII-derived epitope for binding to MHC I molecules. EGFRvIII peptide induces apoptosis, and causes specific immune responses against glioblastoma, especially in combination with Flagellin B.
Apoptosis  
Cancer  
/
HY-177139 CDD-1349
CDD-1349 (Compound 15) is a BRDT-BD2/BRD4-BD2 selective inhibitor. CDD-1349is an analog with sixfold selectivity for BRDT-BD2 versus BRD4-BD2. CDD-1349 has an IC50 of 22 nM against BRDT. CDD-1349 can be studied in research on nonhormonal contraceptive agent.
Epigenetic Reader Domain  
Metabolic or Endocrine Disease  
/
HY-D3182 AldRed 588-A
AldeRed 588-A is a fluorescent labeling reagent and a substrate for aldehyde dehydrogenase (ALDH). AldeRed 588-A is metabolized by functionally active ALDH enzymes, thereby specifically labeling viable ALDHbright cell populations with red-shifted fluorescence. AldeRed 588-A supports one-step isolation and sorting of ALDH-expressing cells (including normal stem cells and cancer stem cells), and can be used in combination with green fluorophores for multicolor experimental applications. AldeRed 588-A is widely applicable to research related to various cancers such as bladder cancer, breast cancer, and head and neck cancer.
Fluorescent Dye   Aldehyde Dehydrogenase (ALDH)  
Cancer  
/
HY-145771 PD-1/PD-L1-IN-20
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC50 of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases.
PD-1/PD-L1  
Cancer  
/
HY-P10950 PD-L1 inhibitory peptide
PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers.
PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-N15522 Bi-magnolignan
Bi-magnolignan is a BRD4 inhibitor that induces DNA damage and apoptosis. Bi-magnolignan inhibits HCT116 cell proliferation with an IC50 value of 2.9 μM.
Epigenetic Reader Domain  
Cancer  
/
HY-P10560 M918
M918 is a cell-penetrating peptide. M918 is internalized by cells through endocytosis and can effectively penetrate a variety of cells in a non-toxic manner. M918 can be used in gene therapy and drug delivery system research.
Biochemical Assay Reagents  
/
HY-D3185 AlDeSense AM
AlDeSense AM is a cell-permeable ALDH1A1-selective fluorescent reporter. AlDeSense AM is oxidized by ALDH1A1, which eliminates photoinduced electron transfer quenching and enhances the fluorescent signal. AlDeSense AM can be used to detect cells with cancer stem cell properties, as well as to monitor the plasticity of cancer stem cells in cell culture systems and animal models. AlDeSense AM is applicable to the study of cancers associated with cancer stem cells, including chronic myeloid leukemia, melanoma, and breast cancer.
Fluorescent Dye   Aldehyde Dehydrogenase (ALDH)  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Melanoma  
/
HY-B0350AG Sodium butyrate (GMP)
Sodium butyrate (GMP) refers to Sodium butyrate (HY-B0350A) of GMP grade. Small molecules of GMP grade can be used as adjuvants in cell therapy. Sodium Butyrate (sodium butanoate) is an inhibitor of HDAC, possessing anti-tumor activity.
HDAC   Autophagy   Apoptosis   Endogenous Metabolite  
/
HY-107614G 1-Oleoyl lysophosphatidic acid sodium (GMP)
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA1 and LPA2, thereby triggering calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer.
LPL Receptor   ROCK   TGF-beta/Smad   TGF-β Receptor  
Ovarian Cancer   Depression   Anxiety or Fear-Related Disease  
/
HY-P2158 Hemoregulatory peptide 5b
Hemoregulatory peptide 5b is an acidic pentapeptide and also a selective inhibitor of myeloid hematopoiesis. Hemoregulatory peptide 5b inhibits myeloid hematopoietic colony formation, as well as the proliferation of committed myeloid hematopoietic stem cells and differentiating myeloid cells. Hemoregulatory peptide 5b exerts anticancer effects against mouse breast cancer and rat glioma. Hemoregulatory peptide 5b exhibits dose-dependent complex hematopoietic regulatory effects in vivo. Hemoregulatory peptide 5b can be used in research related to breast cancer, glioma, and lymphoma.
Drug Intermediate  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Glioma  
/
HY-D3393 JQ1-FITC TFA
JQ1-FITC TFA is a BRD4-binding fluorescent tracer. JQ1-FITC TFA binds to BRD4 BD1, BD2, recombinant bromodomains, and endogenous BRD4 in cell lysates. JQ1-FITC TFA can be used for the research of breast cancer and cancer (Ex/Em = 495/525 nm).
Fluorescent Dye   Epigenetic Reader Domain  
Breast Cancer  
/
HY-P991730 Kiatomab
Kiatomab is a monoclonal antibody targeting the mouse cancer stem cell-specific antigen KIAA1114. Kiatomab has anti-tumor activity. The corresponding isotype control is Mouse IgG2b kappa, Isotype Control (HY-P99982).

Species: Human

Others  
Cancer  
/
HY-B0520AS Benztropine-13C,d3 mesylate
Benztropine-13C,d3 (mesylate) is the 13C- and deuterium labeled Benztropine (mesylate). Benztropine mesylate (Benzatropine mesylate) is an orally active centrally acting anticholinergic agent that can be used for Parkinson's disease research. Benztropine mesylate is an anti-histamine agent and a dopamine re-uptake inhibitor. Benztropine mesylate is also a human D2 dopamine receptor allosteric antagonist. Benztropine mesylate also has anti-CSCs (cancer stem cells) effects.
Isotope-Labeled Compounds   Dopamine Receptor   mAChR   Histamine Receptor  
Cancer   Neurological, Eye or Ear Disease  
/
HY-150516S BET-IN-12
BET-IN-12 is an orally avtive inhibitor of bromodomain and extra-terminal (BET) with an IC50 of 0.9 nM for BRD4.
Epigenetic Reader Domain  
Cancer  
/
HY-P991210 Efzimfotase alfa
Efzimfotase alfa (ALXN-1850) is enzyme replacement therapy agent targeting the deficiency of tissue-nonspecific alkaline phosphatase (TNSALP). Efzimfotase alfa functions by hydrolyzing the substrates of TNSALP, reducing the concentrations of substrates such as inorganic pyrophosphate (PPi) and pyridoxal 5′-phosphate (PLP). Efzimfotase alfa is promising for research of hypophosphatasia (HPP).
Phosphatase  
Blood or Cardio-cerebrovascular Disease  
/
HY-N15380 4,4′-Secalonic acid D
4,4′-Secalonic acid D (Compound 12) is a PARP1 inhibitor. 4,4′-Secalonic acid D induces the accumulation of ROS and DNA damage, activates the caspase-3/GSDME pathway, and triggers apoptosis and pyroptosis of tumor cells by inhibiting PARP1. 4,4′-Secalonic acid D has anti-tumor activity.

Source: Paraconiothyrium sp.

PARP   Reactive Oxygen Species (ROS)   Caspase   Apoptosis   Pyroptosis  
/
HY-N12537A (2R,3S)-PD-1/PD-L1-IN-38
(2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8+T cells and inhibits the signal transduction of PD-1/PD-L1.
Aryl Hydrocarbon Receptor   PD-1/PD-L1  
Cancer  
/
HY-P11858 DP1 peptide
DP1 peptide is a high-affinity ROR1-binding peptide with a Kd value of 74.9 nM. When labeled with 68Ga, DP1 peptide serves as a PET imaging agent, which features rapid tumor uptake, favorable target-to-nontarget ratios in various tumor models, and renal clearance, enabling non-invasive quantitative visualization of ROR1 expression. DP1 peptide can be used in research related to melanoma, hepatocellular carcinoma, colorectal cancer, and non-small cell lung cancer.
ROR   Radionuclide-Drug Conjugates (RDCs)  
Colorectal Cancer   Melanoma   Non-Small Cell Lung Cancer   Hepatitis B Virus Related Hepatocellular Carcinoma  
/
HY-N0242R Fraxinellone (Standard)
Fraxinellone (Standard) is the analytical standard of Fraxinellone. This product is intended for research and analytical applications. Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1.
Reference Standards   PD-1/PD-L1   HIF/HIF Prolyl-Hydroxylase   STAT  
Cancer   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
/
HY-P992337 CS5001 Antibody
CS5001 Antibody is an IgG1 human monoclonal antibody targeting ROR1. CS5001 Antibody can be used for the synthesis of the ADC CS5001. It is applicable to research related to advanced solid tumors and lymphomas. The recommended isotype control is human IgG1 kappa (HY-P99001).

Species: Human

ROR  
Leukemia/Lymphoma/Myeloma  
/
HY-B1896S Piperaquine-d6
Piperaquine-d6 is the deuterium labeled Piperaquine. Piperaquine is a bisquinoline antimalarial agent. Piperaquine can be used in antimalarial research in combination with Artemisinin.
Parasite  
Infection  
/
HY-P11661 DC-peptoid-1
DC-peptoid-1 is a specific binder and crosslinker targeting the phosphorylated Brd4 PDID domain, with a dissociation constant (Kd) of approximately 50-100 μM for human-derived targets. DC-peptoid-1 only binds to phosphorylated PDID and fails to recognize the non-phosphorylated form or other domains (such as Brd4 598-785). DC-peptoid-1 effectively crosslinks with the target protein both in solution and cell lysates. It can successfully capture phosphorylated PDID from complex systems via immobilization, without binding to bacterial-derived non-phosphorylated proteins or other non-specific phosphoproteins. DC-peptoid-1 has the potential to serve as a phosphoprotein-specific antibody substitute for applications such as immunoaffinity purification.
Epigenetic Reader Domain  
Inflammation or Immune System Disease  
/
HY-176346S PDL1, Arg-13C6,15N4, Lys-13C6,15N2
PDL1, Arg-13C36, 15N4, Lys-13C6, 15N2 is the 13C- and 15N-labeled PDL1.
Isotope-Labeled Compounds  
Cancer  
/
HY-P991186 IMM-20059
IMM-20059 is humanized IgG1 monoclonal antibody targeting EPN1. IMM-20059 in combination with Atezolizumab (HY-P9904) significantly enhances tumor regression in the B16.F10 syngeneic melanoma model.

Species: Human

Others  
Cancer  
/
HY-171561G DOTAM-Maleimide triTFA (GMP)
DOTAM-Maleimide triTFA (GMP) is DOTAM-Maleimide triTFA (HY-171561) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOTAM-Maleimide triTFA is a bifunctional chelator.
Biochemical Assay Reagents  
/
HY-P1160A Bay 55-9837 TFA
Bay 55-9837 TFA is a potent and highly selective agonist of VPAC2, with a Kd of 0.65 nM. Bay 55-9837 TFA may be a useful therapy for the research of type 2 diabetes.
GCGR  
Metabolic or Endocrine Disease  
/
HY-10617AS1 Rucaparib-d3
Rucaparib-d3 (AG014699-d3) is the deuterated -labeled Rucaparib (HY-10617A). Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research.
Isotope-Labeled Compounds   PARP  
Ovarian Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer   Castration-Resistant Prostate Cancer  
/
HY-N20707 Castalagin
Castalagin is an orally active natural product with multiple biological activities including antibacterial activity against bacteria and anti-leishmanial activity against Leishmania aethiopica. Castalagin exhibits inhibitory activity against PARP1 and DNA topoisomerase II, with an IC50 of 0.86 μM for bovine PARP1. Castalagin reduces poly (ADP-ribosyl) ation modification in cells. Castalagin binds to the cell envelope of Ruminococcus bromii, increases the ratio of CD8+/FOXP3+CD4+ T cells in the tumor microenvironment, and acts as a prebiotic to enhance the activity of anti-PD-1 therapy. Castalagin induces morphological changes in Leishmania aethiopica promastigotes and inhibits their proliferation. Castalagin inhibits PBP2a-mediated peptidoglycan layer stabilization, disrupts bacterial peptidoglycan assembly, and inhibits and disintegrates bacterial biofilms. Castalagin can be used in research related to diseases such as cancer, leishmaniasis, and bacterial infections.
PARP   Topoisomerase   Penicillin-binding protein (PBP)   PD-1/PD-L1   Bacterial   Parasite  
Cancer   Bacterial Infection   Leishmania Infection  
/
HY-N16067 Penipanoid C
Penipanoid C (Compound 9) is a BRD4 inhibitor. Penipanoid C can be isolated from marine sediment-derived fungus Penicillium paneum SD-44. Penipanoid C has anti-inflammatory activity and cytotoxic activity against the SMMC-7721 cells. Penipanoid C can be used for inflammatory diseases research.

Source: Penicillium oxalicum

Epigenetic Reader Domain  
Inflammation or Immune System Disease  
/
HY-119347R Cirsilineol (Standard)
Cirsilineol (Standard) is the analytical standard of Cirsilineol. This product is intended for research and analytical applications. Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4+ T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice.
Reference Standards   IFNAR   STAT  
Cancer   Inflammation or Immune System Disease  
/
HY-P2564 Human PD-L1 inhibitor III
Human PD-L1 inhibitor III is a human PD-L1 inhibitor.
PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-P992376 huXBR1-402
huXBR1-402 (NBE-002 Antibody) is a high-affinity (Kd=5.8 nM) humanized chimeric rabbit/human monoclonal antibody that targets ROR1. huXBR1-402 specifically binds to the Ig/Fz domain epitope of human ROR1, directly inhibits the proliferation of ROR1-positive tumor cells and induces apoptosis of leukemia cells (apoptosis).

Species: Human

ROR  
Cancer  
/
HY-16910G WIKI4 (GMP)
WIKI4 (GMP) is WIKI4 (HY-16910) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. WIKI4 is a potent tankyrase inhibitor.
Wnt  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-P10273 DOTA-Octreotide
DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is used for research of cancer, through combination with radioactive elements. DOTA-Octreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Radionuclide-Drug Conjugates (RDCs)   Biochemical Assay Reagents  
Cancer  
/
HY-107413G SR11237 (GMP)
SR11237 GMP is SR11237 (HY-107413) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SR11237 is a RXR activator and lipid metabolism regulator that promotes the differentiation of induced neural stem cells into dopaminergic (TH-positive) neurons. SR11237 induces transcriptional regulation of lipogenic genes and cholesterol transporters, increases glycosaminoglycan release, and elevates total cellular triglyceride levels. SR11237 promotes heterodimerization of RXR with Nurr1, thereby enhancing tyrosine hydroxylase expression and facilitating dopamine release. SR11237 produces a synergistic effect when used in combination with bFGF/EGF. SR11237 is mainly used in studies related to osteoarthritis and Parkinson's disease.
RAR/RXR   Tyrosine Hydroxylase  
Inflammation or Immune System Disease   Parkinson's Disease   Osteoarthritis  
/
HY-P11640 Vpr (1-14)
Vpr (1-14) is a viral protein R and acts as an accessory protein of HIV-1. Vpr (1-14) can binds to Cul4A-DDB1-DCAF1 E3 ligase complex and can be used as an E3 ligase-binding component in PROTACs. Vpr (1-14) can be used to synthesize PROTAC BRD4 Degrader-43 (HY-181164).
Ligands for E3 Ligase   HIV  
HIV Infection  
/
HY-P991744 Anti-Mouse CXCR4 Antibody (Cx4Mab-1)
Anti-Mouse CXCR4 Antibody is a monoclonal antibody that specifically recognizes murine CXCR4 (C-X-C chemokine receptor 4), also known as fusin or CD184. CXCR4 is a seven-transmembrane G protein–coupled receptor whose principal endogenous ligand is CXCL12 (stromal cell–derived factor-1α, SDF-1α) and is widely expressed in hematopoietic cells, endothelial cells, neurons, as well as embryonic and adult stem cells. The CXCR4–CXCL12 signaling axis activates multiple downstream pathways, including ERK1/2, Ras, p38 MAPK, PLC/MAPK, and SAPK/JNK, thereby regulating cell survival, proliferation, migration, and stemness maintenance. Aberrant overexpression of CXCR4 is closely associated with poor prognosis and metastasis in various cancers, with CXCR4-positive tumor cells preferentially home to CXCL12-rich tissues such as the liver, bone marrow, lung, and lymph nodes. Accordingly, CXCR4 and its CXCL12-related antagonists emerge as attractive targets for experimental anticancer therapy. Anti-Mouse CXCR4 Antibody is generated using a cell-based immunization and screening strategy and exhibits high affinity for both endogenous and exogenous murine CXCR4. Anti-Mouse CXCR4 Antibody can be used for thestudy of chronic lymphocytic leukemia and multiple myeloma.
CXCR  
Chronic Lymphocytic Leukemia   Multiple Myeloma  
/
HY-P5208 CBLB 612
CBLB 612 is an anti-radiation agent. CBLB 612 can be used in the propagation of mouse and monkey moderate stimulation hematopoietic stem cell (HSC), and lure that they are passed to peripheral blood from bone marrow into. CBLB 612 is an important auxiliary agent for cancer.
Others  
/
HY-N4175 Cucurbitacin A
Cucurbitacin A, a triterpenoid that could be isolated from the Stems of Cucumis melo, shows anti-cancer activity.
Others  
Cancer  
/
HY-P10562 BMV Gag-(7−25)
BMV Gag-(7 25) is an arginine-rich peptide with cell-penetrating ability. BMV Gag-(7 25) can be used in drug delivery and gene therapy research.
TMV  
/
HY-N12537 PD-1/PD-L1-IN-38
PD-1/ PD-L1-in-38 is a PD-1/PD-L1 inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8+ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity.
PD-1/PD-L1  
/
HY-N7589 Demethylcarolignan E
Demethylcarolignan E is a phenylpropanoid ester that can be isolated from the stems of Hibiscus taiwanensi. Demethylcarolignan E has cytotoxicity against human cancer lines A549 and MCF-7 (IC50: <10 μg/mL).
Others  
/
HY-165394 Melafolone
Melafolone is a potent dual COX-2/EGFR inhibitor with IC50s of 13.2 μM (COX-2) and 17.4 μM (EGFR). Melafolone enhances the effect of anti-PD-1 through vascular normalization and PD-L1 downregulation via the PI3K/Akt pathway in Lewis lung carcinoma (LLC) and CMT167 models. Melafolone can be used for lung cancer research.
COX   EGFR   PD-1/PD-L1   PI3K   Akt  
/
HY-P992448 RC98
RC98 is a monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) and acts as a selective PD-L1 inhibitor. RC98 binds specifically to human and cynomolgus monkey PD-L1. RC98 blocks the interaction between PD-L1 and its receptor PD-1 to reverse T-cell inactivation mediated by PD-1/PD-L1 signaling. RC98 enhances the cytotoxic T-lymphocyte-mediated anti-tumor immune response against PD-L1-expressing tumor cells. RC98 can be used for the research of tumor immunity and solid tumors.

Species: Human

PD-1/PD-L1  
Cancer  
/
HY-P992519 PF-06940434
PF-06940434 (ADWA-11) is a monoclonal antibody targeting integrin αvβ8. PF-06940434 inhibits αvβ8-mediated TGF-β activation. PF-06940434 increases the accumulation of tumor-infiltrating CD8+ T cells and upregulates the expression of granzyme B and TNF-γ. PF-06940434 blocks the inhibitory effect of CD4+CD25+ T cells on the cytotoxic activity of tumor CD8+ T cells. PF-06940434 enhances the anti-tumor efficacy of combination therapies with other immunomodulators or radiotherapy and induces long-term anti-tumor immunity. PF-06940434 can be used in the research of squamous cell carcinoma, breast cancer, colon cancer, and prostate adenocarcinoma.
Integrin   TNF Receptor   TGF-β Receptor  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Squamous Cell Carcinoma  
/
HY-15244G Alpelisib (GMP)
Alpelisib GMP is Alpelisib (HY-15244) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome.
PI3K   Apoptosis  
/
HY-12299G WH-4-023 (GMP)
WH-4-023 GMP is WH-4-023 (HY-12299) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. WH-4-023 (Dual LCK/SRC inhibitor) is a Lck/Src dual target inhibitor with functions in stem cell maintenance and differentiation regulation. WH-4-023 blocks epithelial-mesenchymal transition, supports the self-renewal of porcine embryonic stem cells, and inhibits their differentiation into mesoderm and endoderm. WH-4-023 is a key component of 3i/LAF medium, and enables the stable establishment and long-term maintenance of porcine pre-gastrulation epiblast stem cell lines. Removal of WH-4-023 reduces the expression of pluripotency factors in porcine and human extended pluripotent stem cells. WH-4-023 can be applied to relevant studies such as non-small cell lung cancer resistant to EGFR-TKIs.
Src  
Non-Small Cell Lung Cancer  
/
HY-P11859 NP1
NP1 is a NOTA-chelated linear precursor based on the ROR1-targeting peptide. After labeling with [18F]AlF, NP1 yields [18F]AlF-NP1, a PET imaging probe with excellent ROR1 specificity (KD = 141.7 nM), rapid tumor uptake and high target-to-background ratio, which is suitable for non-invasive visualization of various ROR1-overexpressing tumors.
ROR   Radionuclide-Drug Conjugates (RDCs)  
Cancer  
/
HY-N0565AG Doxycycline (hydrochloride) (GMP)
Doxycycline hydrochloride GMP is Doxycycline (hydrochloride) (HY-N0565A) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Doxycycline hydrochloride is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline hydrochloride is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline hydrochloride also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline hydrochloride induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline hydrochloride also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline hydrochloride has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
Apoptosis   MMP   Akt   PI3K  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Breast Cancer   Prostate Cancer   Bladder Cancer  
/
HY-N9149 Cryptanoside A
Cryptanoside A, a cardiac glycoside epoxide, can be isolated from the stems of Cryptolepis dubia. Cryptanoside A has potent cytotoxicity against cancer cells. Cryptanoside A also inhibits Na+/K+-ATPase activity. Cryptanoside A increases the expression of Akt and the p65 subunit of NF-κB.
Na+/K+ ATPase   Akt   NF-κB  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-B0965S Thioridazine 2-Sulfone-d3
Thioridazine-d3 2-Sulfone is the deuterium labeled Thioridazine hydrochloride. Thioridazine hydrochloride, an orally active antagonist of the dopamine receptor D2 family proteins, exhibits potent anti-psychotic and anti-anxiety activities. Thioridazine hydrochloride is also a potent inhibitor of PI3K-Akt-mTOR signaling pathways with anti-angiogenic effect. Thioridazine hydrochloride shows antiproliferative and apoptosis induction effects in various types of cancer cells, with specificity on targeting cancer stem cells (CSCs).
Isotope-Labeled Compounds   Bacterial   Apoptosis   5-HT Receptor   Dopamine Receptor   Autophagy  
Cancer   Infection   Neurological, Eye or Ear Disease  
/
HY-118865S Piperaquine-d6 tetraphosphate
Piperaquine-d6 (tetraphosphate) is the deuterium labeled Piperaquine tetraphosphate. Piperaquine tetraphosphate is a bisquinoline antimalarial agent. Piperaquine phosphate can be used in antimalarial research in combination with Artemisinin.
Isotope-Labeled Compounds   Parasite  
Infection  
/
HY-113432S2 Nudifloramide-13C,d3
Nudifloramide-13C,d3 (2PY-13C,d3) is the 13C- and deuterium labeled Nudifloramide (HY-113432). Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro.
Isotope-Labeled Compounds   PARP   Endogenous Metabolite  
/
HY-P990851 Anti-c-Kit/CD117 Antibody (SR-1)
Anti-c-Kit/CD117 Antibody (SR-1) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human c-Kit/CD117. Anti-c-Kit/CD117 Antibody (SR-1) binds to the extracellular domain of human c-Kit (also known as CD117) and blocks stem cell factor (SCF) binding to CD117. Anti-c-Kit/CD117 Antibody (SR-1) can be used for the researches of cancer and immunology, such as gastrointestinal stromal tumor (GIST) and xenograft.

Species: Human

c-Kit  
Cancer   Inflammation or Immune System Disease  
/
HY-P991395 TQB2618
TQB2618 is a human IgG4 monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. TQB2618 activates immune cell function and induces significant anti-tumor activity when used in combination with anti-PD-1 agents.

Species: Human

Tim3  
Cancer  
/
HY-16106S1 Talazoparib-d4
Talazoparib-d4 (BMN-673-d4) is deuterium labeled Talazoparib. Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity.
Isotope-Labeled Compounds   PARP  
Cancer  
/
HY-14743R Golotimod (Standard)
Golotimod (Standard) is the analytical standard of Golotimod. This product is intended for research and analytical applications. Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).
Bacterial   STAT   Reference Standards  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-N15294 3β-Hydroxy-27-p-Z-coumaroyloxyurs-12-en-28-oic acid
3β-Hydroxy-27-p-Z-coumaroyloxyurs-12-en-28-oic acid (compound 8) is a triterpenoid ester HIV-1 protease inhibitor with the potential for use in the antiretroviral combination therapy of AIDS.
HIV   HIV Protease  
Infection  
/
HY-N3262 Methylisopelletierine
Methylisopelletierine is a piperidine alkaloid found in the leaves and stem barks of Punica granatum. It serves as the direct biosynthetic precursor of pseudopelletierine and can undergo cyclization to form pseudopelletierine. Methylisopelletierine can be used in studies related to colorectal cancer.
Others  
Colorectal Cancer  
/
HY-10617AS Rucaparib-d8
Rucaparib-d8 (AG014699-d8 ) is deuterium labeled Rucaparib. Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research.
Isotope-Labeled Compounds   PARP  
/
HY-129283 Goralatide
Goralatide is a compound that regulates the thermal sensitivity of hematopoietic progenitor cells. It can reduce the thermal sensitivity of normal hematopoietic progenitor cells and increase the difference in thermal sensitivity between leukemia progenitor cells and normal progenitor cells, thereby increasing the inhibition window of hyperthermia therapy.
Ras  
/
HY-132559S PD-166285-d4
PD-166285-d4 is the deuterium labeled PD-166285.
Isotope-Labeled Compounds  
/
HY-P990823 Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11) is rat-derived IgG2b κ type antibody inhibitor, targeting to PD-L1/B7-H1. Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11) can block PD-L1/ B7-1 interactions and does not block PD-L1/PD-1 interactions. Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11) can be used for the researches of cancer, infection, immunology and metabolic disease, such as MB49 tumor, heart graft and diabetes.

Species: Mouse

PD-1/PD-L1  
Cancer   Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P2474 Human PD-L1 inhibitor I
Human PD-L1 inhibitor I is a hPD-1 peptide ligand, with a KD of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1.
PD-1/PD-L1  
Cancer  
/
HY-P2478A Human PD-L1 inhibitor V TFA
Human PD-L1 inhibitor V TFA, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1.
PD-1/PD-L1  
Inflammation or Immune System Disease  
/
HY-14743 Golotimod
Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).
Bacterial   STAT  
Inflammation or Immune System Disease   Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Mycobacterium Tuberculosis Infection   Obesity  
/
HY-W759435 Niraparib-d5
Niraparib-d5 (MK-4827-d5) is the deuterium labeled Niraparib (HY-10619). Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.
Isotope-Labeled Compounds   PARP   Apoptosis  
Cancer  
/
HY-P991689 Girancitug
Girancitug is a humanized IgG1κ monoclonal antibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research.

Species: Human

VEGFR  
Cancer  
/
HY-161096 Antitumor agent-127
Antitumor agent-127 (compound 1) is a parent macrocyclic peptide. Antitumor agent-127 displays nanomolar cell-based binding to ROR1 and relatively good internalization in 786-O and MDA-MB-231 tumor cell lines.
ROR  
Cancer  
/
HY-W106860 9H-Carbazole-3-carbaldehyde
9H-Carbazole-3-carbaldehyde (3-Formylcarbazole) is a carbazole compound and an anticancer agent. 9H-Carbazole-3-carbaldehyde is present in the stems of Clausena lansium (Lour.) Skeels. 9H-Carbazole-3-carbaldehyde can be used in the research of cervical cancer, leukemia, non-small cell lung cancer and liver cancer.
Drug Intermediate  
Liver Cancer   Cervical Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer  
/
HY-N1202 Sitostanetriol
Sitostanetriol (Sitostane-3β,5α,6β-triol) is a steroidal compound found in the stems of Casearia membranacea. Sitostanetriol exhibits no significant cytotoxic activity in vitro. Sitostanetriol is used in research related to natural product chemistry, leukemia, lung cancer, and colorectal cancer.
Biochemical Assay Reagents  
Lung Cancer   Colorectal Cancer   Leukemia/Lymphoma/Myeloma  
/
HY-P10217 PD-1/PD-L1-IN-42
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC50 of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy.
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-N0488S Vincristine-d3 sulfate
Vincristine-d3 sulfate is the deuterium labeled Vincristine sulfate. Vincristine sulfate (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas.
Isotope-Labeled Compounds   Apoptosis   Microtubule/Tubulin   Mitosis  
Cancer  
/
HY-135319 Strictinin
Strictinin is an orally active phenolic compound. Strictinin reduces xanthine oxidase activity, uric acid production, and the activation of ERK1/2, JNK, NF-κB, and NLRP3 inflammasome components in hepatocytes treated with Xanthine (HY-W017389). Strictinin decreases elevated serum uric acid levels and enhanced xanthine oxidase activity in mice treated with potassium oxonate. Strictinin acts as a ROR1 inhibitor and exhibits anticancer activity against highly aggressive non-androgen-dependent prostate cancer. Strictinin induces cancer cell apoptosis (apoptosis), arrests cell cycle, and inhibits cancer cell migration, invasion, and epithelial-mesenchymal transition. Strictinin modulates gut microbiota, inhibits bacterial growth and biofilm formation, accelerates small intestinal transit, and blocks viral entry and replication. Strictinin can be used in research related to hyperuricemia, androgen receptor-negative non-androgen-dependent prostate cancer, triple-negative breast cancer, bacterial infections, constipation, coronavirus infections, dental caries, and infections caused by influenza A, influenza B, and human parainfluenza virus type 1.
Bacterial   Antibiotic   ERK   JNK   NF-κB   ROR   Apoptosis   Caspase   GSK-3   Akt   PI3K  
Inflammation or Immune System Disease   Prostate Cancer   Coronavirus Infection   Bacterial Infection   Triple-Negative Breast Cancer   Influenza Virus Infection   Gout  
/
HY-P2478 Human PD-L1 inhibitor V
Human PD-L1 inhibitor V, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1.
PD-1/PD-L1  
Inflammation or Immune System Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-P2477 Human PD-L1 inhibitor IV
Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a Kd value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1.
PD-1/PD-L1  
Inflammation or Immune System Disease  
/
HY-B0965AS Thioridazine-d3 hydrochloride
Thioridazine-d3 (hydrochloride) is the deuterium labeled Thioridazine. Thioridazine, an antagonist of the dopamine receptor D2 family proteins, exhibits potent anti-psychotic and anti-anxiety activities. Thioridazine is also a potent inhibitor of PI3K-Akt-mTOR signaling pathways with anti-angiogenic effect. Thioridazine shows antiproliferative and apoptosis induction effects in various types of cancer cells, with specificity on targeting cancer stem cells (CSCs).
Dopamine Receptor   Apoptosis   5-HT Receptor   Autophagy   Bacterial  
Neurological, Eye or Ear Disease  
/
HY-P2470 Human PD-L1 inhibitor II
Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.
PD-1/PD-L1  
Cancer  
/
HY-N3213 Naringenin triacetate
Naringenin triacetate is a flavonoid isolated from plant, exhibits a good binding affinity with multiple crystal structures of first bromodomain BRD4 (BRD4 BD1).
Epigenetic Reader Domain  
Leukemia/Lymphoma/Myeloma  
/
HY-P10446 TAT-PiET-PROTAC
TAT-PiET-PROTAC is a proteolysis-targeting chimera (PROTAC)-modified TAT-PiET (HY-P10445), which is a cell-penetrating peptide targeting the extra-terminal (ET) domain of BRD4. TAT-PiET-PROTAC can reduce BRD4 and JMJD6 levels and inhibit cell proliferation. TAT-PiET-PROTAC also resists the endocrine resistance of ERα-positive breast cancer cells. TAT-PiET-PROTAC can be used for the research of cancer, such as breast cancer.
Epigenetic Reader Domain   PROTACs  
/
HY-W748509 Pipernonaline
Pipernonaline is a piperine derivative with antiprostate cancer activity. Pipernonaline inhibits the proliferation of androgen-dependent/independent LNCaP/PC-3 prostate cells. Pipernonaline activates caspase-3 and promotes procaspase-3/PARP cleavage. Pipernonaline also mediates reactive oxygen species (ROS) production, increased intracellular Ca(2+), and mitochondrial membrane depolarization.
Caspase   Apoptosis  
/
HY-N0565S1 Doxycycline-d3 (hyclate) (major)
Doxycycline-d3 hyclate (major) is the deuterium labeled Doxycycline hyclate (HY-N0565B). Doxycycline hyclate is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline hyclate is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline hyclate also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline hyclate induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline hyclate also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline hyclate has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
Isotope-Labeled Compounds   MMP   Parasite   Bacterial   Antibiotic   Apoptosis   Akt   PI3K  
Cancer   Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-N8389 Globulol
Globulol is a terpenoid metabolite and Antimicrobial agent. Globulol can be isolated from Alpinia oxyphylla Miq. Globulol binds to PAK4, reduces the expression level of PAK4 in cancer cells, decreases the phosphorylation of AKT, and downregulates the expressions of STAT3, phosphorylated STAT3, and PD-L1. Globulol promotes the secretion of CCL4 by cancer cells. Globulol reduces the viability and proliferation ability of cancer cells, induces G0/G1 cell cycle arrest and Apoptosis in cancer cells, and inhibits cancer cell migration and the integrity of 3D tumor spheres. Globulol enhances the relevant effects of anti-PD-1 agents in the cancer cell microenvironment. Globulol exhibits anticancer activity against liver cancer. Globulol inhibits the mycelial growth of phytopathogenic fungi and the growth of phytopathogenic bacteria. Globulol can be used in studies related to hepatocellular carcinoma.
Bacterial   Fungal   PAK   Akt   STAT   PD-1/PD-L1   Apoptosis   CCR  
Liver Cancer   Bacterial Infection   Fungal Infection  
/
HY-P990067 Evunzekibart
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.

Species: Human

TNF Receptor  
Cancer  
/
HY-P99922 Encelimab
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft).

Species: Human

LAG-3  
Cancer  
/
HY-Z0283S Benzamide-15N
Benzamide-15N is a 15N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP).
Endogenous Metabolite   PARP  
/
HY-N14001 Naamidine J
Naamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM). Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors.

Source: Pericharax heteroraphis

TNF Receptor   Interleukin Related   Arginase   PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-103048A PD-1/PD-L1-IN 3 TFA
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases.
PD-1/PD-L1  
/
HY-113081R 1-Methyladenosine (Standard)
1-Methyladenosine (Standard) is the analytical standard of 1-Methyladenosine. This product is intended for research and analytical applications. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis. In Vitro:Compared to surrounding tumor tissues, 1-methyladenosine methylation in RNA is aberrantly elevated in hepatocellular carcinoma (HCC) cell lines and liver cancer stem cells (CSCs). Methylated 1-methyladenosine can promote cholesterol synthesis and activate the Hedgehog signaling pathway by enhancing the translation of PPARδ in liver CSCs, ultimately driving the self-renewal and tumorigenesis of liver cancer stem cells.
Reference Standards   Endogenous Metabolite   PPAR   Hedgehog  
Cancer  
/
HY-N2732 6-Prenylapigenin
6-Prenylapigenin (6-Prenyl-4',5,7-trihydroxyflavone; 6-C-Prenylapigenin) is a prenylated flavonoid that exists in the stems and leaves of Maclura pomifera. 6-Prenylapigenin exhibits cytotoxicity against cancer cells such as leukemia cells and solid tumor cells.
Others  
Cancer  
/
HY-B0803S1 Lumefantrine-d9
Lumefantrine-d9 is the deuterium labeled Lumefantrine. Lumefantrine is an antimalarial drug, used in combination with Artemether. The artemether-lumefantrine (AL) as the first- and second-line anti-malarial drugs.
Isotope-Labeled Compounds   Parasite   Autophagy  
Infection  
/
HY-P991209 Nebratamig
Nebratamig (GNC-035) is an anti-ROR1/anti-CD3/anti-PD-L1/anti-4-1BB tetra-specific antibody with potential immunostimulatory and antineoplastic activities.

Species: Human

ROR   CD3   PD-1/PD-L1  
Inflammation or Immune System Disease   Breast Cancer  
/
HY-D0957 Ethyl Violet
Ethyl Violet is a triphenylmethane cationic dye with antibacterial activity. Ethyl Violet is applicable to research related to antibacterial therapy and histological staining.
Fluorescent Dye   Bacterial  
Staphylococcus Aureus Infection  
/
HY-P990828 Anti-PD-L1/B7-H1 Antibody (29E.2A3)
Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human PD-L1/B7-H1. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can block the binding of PD-1 to PD-L1. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can be used for the research of infection, such as hepatitis C virus (HCV).

Species: Human

PD-1/PD-L1  
Infection  
/
HY-P991319 TAB-004
TAB-004 is a murine IgG1 monoclonal antibody that specifically binds to the tumor-associated hypoglycosylated mucin 1 (tMUC1), with high selectivity for human tMUC1. TAB-004 can be conjugated with Indocyanine green (ICG) (HY-D0711) for in vivo targeted imaging. TAB-004 can be used for the research of early detection, tumor progression monitoring and cancer stem cell targeting in breast cancer and pancreatic cancer.

Species: Human

Others  
Pancreatic Cancer   Triple-Negative Breast Cancer  
/
HY-113432R Nudifloramide (Standard)
Nudifloramide (Standard) is the analytical standard of Nudifloramide. This product is intended for research and analytical applications. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro.

Source: Human Blood, Feces, Urine

Reference Standards   Endogenous Metabolite   PARP  
Metabolic or Endocrine Disease  
/
HY-15147G XAV-939 (GMP)
XAV-939 (GMP) is XAV-939 (HY-15347) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. XAV-939 is a tankyrase inhibitor.
PARP  
Cancer   Neurological, Eye or Ear Disease  
/
HY-113432S Nudifloramide-d3
Nudifloramide-d3 (2PY-d3) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro.
Endogenous Metabolite   PARP  
Metabolic or Endocrine Disease  
/
HY-P10273A DOTA-Octreotide TFA
DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Radionuclide-Drug Conjugates (RDCs)   Biochemical Assay Reagents  
/
HY-W011338S Benzyl butyl phthalate-d4
Benzyl butyl phthalate-d4 is the deuterium labeled Benzyl butyl phthalate. Benzyl butyl phthalate, a member of phthalic acid esters (PAEs), can trigger the migration and invasion of hemangioma (HA) cells via upregulation of Zeb1. Benzyl butyl phthalate activates aryl hydrocarbon receptor (AhR) in breast cancer cells to stimulate SPHK1/S1P/S1PR3 signaling and enhances formation of metastasis-initiating breast cancer stem cells (BCSCs).
Aryl Hydrocarbon Receptor  
/
HY-NP043 Avidin-Cy3
Avidin-Cy3 is Cy3-labeled Avidin. Avidin has excellent affinity with biotin and is often used in combination with biotin for immunoassays to detect the location of antigens in tissues.
Fluorescent Dye  
/
HY-P99261 Demcizumab
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models.

Species: Human

Notch  
Cancer  
/
HY-113352 7-Methylguanine
7-Methylguanine is an orally active and competitive PARP-1 inhibitor with a Ki value of 61 μM. 7-Methylguanine is a metabolite of nucleic acids. 7-Methylguanine has anticancer activity against uterine sarcoma and colon adenocarcinoma. 7-Methylguanine is used as a probe for protein-DNA interactions.
Endogenous Metabolite   PARP  
Cancer  
/
HY-NP037 Avidin-HRP
Avidin-HRP is Horseradish Peroxidase (HRP) Avidin. Avidin has excellent affinity with biotin and is often used in combination with biotin for immunoassays to detect the location of antigens in tissues.
Others  
/
HY-W009062 MePhos
MePhos is an o-BPP ligand. The combination of MePhos and silver carbonate serves as a catalyst for H/D exchange reactions.
Biochemical Assay Reagents  
/
HY-W018597 2-Chloro-N-methylethanamine hydrochloride
2-Chloro-N-methylethanamine hydrochloride is a nitro compound that can be used to synthesize PD-1 inhibitors.
Biochemical Assay Reagents  
/
HY-13257G Thiazovivin (GMP)
Thiazovivin (GMP) is Thiazovivin (HY-13257) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Thiazovivin is a potent ROCK inhibitor.
ROCK  
Cancer  
/
HY-P10810 QPH-FR
QPH-FR is a LGR5 inhibitor. QPH-FR competitively binds to LGR5 and prevents the formation of the LGR5/RSPO1 complex. QPH-FR promotes RNF43/ZNRF3-mediated ubiquitination of FZD receptors, inhibits the Wnt β-catenin signaling pathway, and reduces the stemness of colorectal cancer cells. QPH-FR is applicable to relevant research on colorectal cancer.
Wnt   β-catenin  
Colorectal Cancer  
/
HY-145746 Sulfo-Cy5 azide
Sulfo-Cy5 azide is a near-infrared fluorescent probe with favorable click chemistry reactivity. Sulfo-Cy5 azide enables fluorescence imaging, tissue and cellular visualization of PD-L1 in tumors, and site-specific modification of anti-PD-L1 antibodies. Sulfo-Cy5 azide has been employed for RNA labeling and imaging. Sulfo-Cy5 azide can be conjugated to targeting agents for fluorescence imaging in atherosclerosis and breast cancer models (Ex/Em = 645/670 nm).
Fluorescent Dye   PD-1/PD-L1  
Breast Cancer   Atherosclerosis and Inflammation  
/
HY-137042 Cyanine5 alkyne
Cyanine5 alkyne (Alkyne-Cy5) is a fluorescent dye used to label azide proteins and can be used to analyse post-translational modifications of proteins, glycosylation etc. Cyanine5 alkyne can also be used as a mitochondrial OXPHOS inhibitor to inhibit the growth of cancer stem cells (CSC). Cyanine5 alkyne is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Oxidative Phosphorylation   Mitochondrial Metabolism  
/
HY-P1160 Bay 55-9837
Bay 55-9837 is a potent and highly selective agonist of VPAC2, with a Kd of 0.65 nM. Bay 55-9837 may be a useful therapy for the research of type 2 diabetes.
GCGR  
Metabolic or Endocrine Disease  
/
HY-113432 Nudifloramide
Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro.
Endogenous Metabolite   PARP  
Metabolic or Endocrine Disease   Breast Cancer   Pancreatic Cancer   Ovarian Cancer  
/
HY-19204 Zinc phthalocyanine
Zinc phthalocyanine (ZnPc) is commonly applied in industry (catalysts, photoconductors) and biomedical (photodynamic therapy, PDT). Zinc phthalocyanine can be used to photooxidise cyclohexane and is promising for research of solar-cell applications.
Ligands for Target Protein for PROTAC   Reactive Oxygen Species (ROS)   Apoptosis   Caspase  
Cancer  
/
HY-171821 PF-08046054
PF-08046054 (SGN-PDL1V) is a PD-L1-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors
Antibody-Drug Conjugates (ADCs)   PD-1/PD-L1  
Cancer  
/
HY-P99175 KWAR 23
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

Species: Human

CD47  
Cancer  
/
HY-P99956 Zilovertamab vedotin
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer.
Antibody-Drug Conjugates (ADCs)   Apoptosis  
/
HY-P73717 PD-L1 Protein, Canine (HEK293, Fc)
PD-L1 Protein, Canine (HEK293, Fc) is a trans-membrane protein that is considered to be a co-inhibitory factor of the immune response. The amino acid sequence of PD-L1 is encoded by 7 exons, which form a protein of ~40 kDa. PD-L1 is a type I transmembrane protein, is part of the immunoglobulin (Ig) superfamily and is composed of IgV-like and IgC-like extracellular domains, a hydrophobic transmembrane domain and a short cytoplasmic tail composed of 30 amino acids. PD-L1 can combine with PD-1 to reduce the proliferation of PD-1 positive cells, inhibit their cytokine secretion and induce apoptosis. PD-L1 also plays an important role in various malignancies where it can attenuate the host immune response to tumor cells. PD-L1 Protein, Canine (HEK293, Fc) is the recombinant canine-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Canine; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Epithelial cell CD Proteins PD-L1

/
HY-P73364 PD-L1 Protein, Rat (HEK293, Fc)
PD-L1 (Programmed death-ligand 1) critically regulates T cell proliferation and migration, acting as a biomarker for periodontitis and pre-eclampsia. CD274 is its human ortholog. Biased expression in the thymus (RPKM 102.9), spleen (RPKM 58.3), and other tissues emphasizes PD-L1's centrality in immune regulation across diverse physiological and pathological conditions. PD-L1 Protein, Rat (HEK293, Fc) is the recombinant rat-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Rat; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Epithelial cell CD Proteins PD-L1

/
HY-P73365 PD-L1 Protein, Rat (HEK293, His)
PD-L1 (Programmed death-ligand 1) critically regulates T cell proliferation and migration, acting as a biomarker for periodontitis and pre-eclampsia. CD274 is its human ortholog. Biased expression in the thymus (RPKM 102.9), spleen (RPKM 58.3), and other tissues emphasizes PD-L1's centrality in immune regulation across diverse physiological and pathological conditions. PD-L1 Protein, Rat (HEK293, His) is the recombinant rat-derived PD-L1 protein, expressed by HEK293 , with C-10*His labeled tag.

Species: Rat; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Epithelial cell CD Proteins PD-L1

/
HY-P702585 PARP2 Protein, Human (sf9, His)
PARP2 Protein, Human (sf9, His) is the recombinant human-derived PARP2, expressed by Sf9 insect cells , with N-6*His labeled tag. ,

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Transferases (EC 2)

/
HY-P73337 PARP1 Protein, Mouse (sf9, His)
PARP, a poly-ADP-ribosyltransferase, catalyzes poly-ADP-ribosylation, crucial for DNA repair. This protein irreversibly binds to DNA breaks, disrupting repair processes and triggering DNA damage-induced apoptosis. PARP1 Protein, Mouse (sf9, His) is the recombinant mouse-derived PARP protein, expressed by Sf9 insect cells , with N-His labeled tag.

Species: Mouse; Source: Sf9 insect cells

Enzymes & Regulators Transferases (EC 2)

/
HY-P70663 PD-L1 Protein, Human (HEK293, Flag)
The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (HEK293, Flag) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-Flag labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Epithelial cell CD Proteins PD-L1

/
HY-P70564 PD-L1 Protein, Cynomolgus (HEK293, His)
CD274 molecule, also known as programmed death ligand 1 (PD-L1), binds to the checkpoint suppressor molecule PD-1 to inhibit TCR-mediated IL-2 production and T cell proliferation signaling. PD-L1 is involved in the PI3K/JAK/STAT signaling pathway to promote tumor occurrence. PD-L1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived PD-L1 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Cynomolgus; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Epithelial cell CD Proteins PD-L1

/
HY-P70657 PD-L1 Protein, Human (HEK293, mFc)
The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (HEK293, mFc) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-mFc labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Epithelial cell CD Proteins PD-L1

/
HY-P78192 PD-L1 Protein, Human (Biotinylated, HEK293, His-Avi)
The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Epithelial cell CD Proteins PD-L1

/
HY-P73716 PD-L1 Protein, Mouse (HEK293, His-Fc)
PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (HEK293, His-Fc) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-hFc, C-His labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Epithelial cell CD Proteins PD-L1

/
HY-P77819 PD-L1 Protein, Mouse (Biotinylated, HEK293, His)
PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (Biotinylated, HEK293, His) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules Macrophage CD Proteins Monocyte CD Proteins Epithelial cell CD Proteins PD-L1

/
HY-P703622 PARP7 Protein, Human (His, Avi)
PARP7 Protein, Human (His, Avi) is the recombinant human-derived PARP7, expressed by E. coli , with His, Avi labeled tag. ,

Species: Human; Source: E. coli

Enzymes & Regulators Transferases (EC 2)

/
HY-P701632 TNKS1 Protein, Human
The TNKS1 protein is a polyADP-ribosyltransferase that is integral to multiple cellular processes, including the Wnt signaling pathway, telomere length regulation, and vesicle trafficking. In Wnt signaling, TNKS1 activates this pathway by poly-ADP-ribosylating AXIN1 and AXIN2, promoting their degradation. TNKS1 Protein, Human is the recombinant human-derived TNKS1 protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

Enzymes & Regulators Transferases (EC 2)

/
HY-P78617 ROR1 Protein, Rat (HEK293, His)
ROR1 protein is an important member of the Tyr protein kinase family in the protein kinase superfamily and plays a key role as a tyrosine kinase in cell signaling and regulation. Its classification emphasizes its importance in phosphorylation events and shares conserved features with related kinases. ROR1 Protein, Rat (HEK293, His) is the recombinant rat-derived ROR1 protein, expressed by HEK293 , with C-10*His labeled tag.

Species: Rat; Source: HEK293

CAR-T Related Proteins Receptor Proteins Enzymes & Regulators ROR1 Receptor Tyrosine Kinases Protein Tyrosine Kinases ROR family

/
HY-P77825 ROR1 Protein, Canine (HEK293, His)
ROR1 protein is an important member of the Tyr protein kinase family in the protein kinase superfamily and plays a key role as a tyrosine kinase in cell signaling and regulation. Its classification emphasizes its importance in phosphorylation events and shares conserved features with related kinases. ROR1 Protein, Canine (HEK293, His) is the recombinant canine-derived ROR1 protein, expressed by HEK293 , with C-His labeled tag.

Species: Canine; Source: HEK293

CAR-T Related Proteins Receptor Proteins Enzymes & Regulators ROR1 Receptor Tyrosine Kinases Protein Tyrosine Kinases ROR family

/
HY-P78510 ROR1 Protein, Human (HEK293, His-Avi)
ROR1 protein's minimal kinase activity in vitro suggests an improbable role as a tyrosine kinase in vivo. It serves as a receptor for WNT5A, activating NFkB signaling and potentially inhibiting WNT3A signaling. Notably, ROR1 plays a vital role in the inner ear, facilitating innervation of auditory hair cells by spiral ganglion neurons. ROR1 Protein, Human (HEK293, His-Avi) is the recombinant human-derived ROR1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins Receptor Proteins Enzymes & Regulators ROR1 Receptor Tyrosine Kinases Protein Tyrosine Kinases ROR family

/
HY-P78815 ROR1 Protein, Human (Biotinylated, HEK293, Fc-Avi)
ROR1 protein's minimal kinase activity in vitro suggests an improbable role as a tyrosine kinase in vivo. It serves as a receptor for WNT5A, activating NFkB signaling and potentially inhibiting WNT3A signaling. Notably, ROR1 plays a vital role in the inner ear, facilitating innervation of auditory hair cells by spiral ganglion neurons. ROR1 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived ROR1 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins Receptor Proteins Enzymes & Regulators Biotinylated Proteins ROR1 Receptor Tyrosine Kinases Protein Tyrosine Kinases ROR family

/
HY-P78816 ROR1 Protein, Human (Biotinylated, HEK293, Avi)
ROR1 protein's minimal kinase activity in vitro suggests an improbable role as a tyrosine kinase in vivo. It serves as a receptor for WNT5A, activating NFkB signaling and potentially inhibiting WNT3A signaling. Notably, ROR1 plays a vital role in the inner ear, facilitating innervation of auditory hair cells by spiral ganglion neurons. ROR1 Protein, Human (Biotinylated, HEK293, Avi) is the recombinant human-derived ROR1 protein, expressed by HEK293 , with C-Avi labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins Receptor Proteins Enzymes & Regulators Biotinylated Proteins ROR1 Receptor Tyrosine Kinases Protein Tyrosine Kinases ROR family

/
HY-P78032 ROR1 Protein, Mouse (HEK293, His)
ROR1 protein shows minimal kinase activity in vitro, indicating an improbable role as a tyrosine kinase in vivo.It functions as a receptor for WNT5A, activating NFkB signaling and potentially inhibiting WNT3A signaling.Additionally, ROR1 plays a vital role in the inner ear, aiding the innervation of auditory hair cells by spiral ganglion neurons.ROR1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived ROR1 protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

CAR-T Related Proteins Receptor Proteins Enzymes & Regulators ROR1 Receptor Tyrosine Kinases Protein Tyrosine Kinases ROR family

/
HY-P706167 PARP1 Protein, Human (Active, sf9, His-GST)
The PARP1 protein is a polyADP-ribosyltransferase that crucially mediates polyADP-ribosylation (PARsylation) in DNA repair, including base excision and double-strand breaks. By interacting with factors such as HPF1 and NMNAT1, the specificity of PARP1 extends to various amino acids. PARP1 Protein, Human (Active, sf9, His-GST) is the recombinant human-derived PARP1 protein, expressed by Sf9 insect cells , with N-6*His, N-GST labeled tag.

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Transferases (EC 2)

/
HY-P701951 PARP14 Protein, Human
The PARP14 protein is an ADP-ribosyltransferase that uniquely mono-ADP-ribosylates glutamic acid residues on target proteins such as STAT1 and STAT6, unlike PARP1 and PARP2. It catalyzes STAT1 mono-ADP ribosylation at “Glu-657” and “Glu-705”, reduces STAT1 phosphorylation and inhibits the production of pro-inflammatory cytokines in macrophages following IFNG stimulation. PARP14 Protein, Human is the recombinant human-derived PARP14 protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

Enzymes & Regulators Transferases (EC 2)

/
HY-P701952 PARP14 Protein, Human (His, StrepⅡ)
The PARP14 protein is an ADP-ribosyltransferase that uniquely mono-ADP-ribosylates glutamic acid residues on target proteins such as STAT1 and STAT6, unlike PARP1 and PARP2. It catalyzes STAT1 mono-ADP ribosylation at “Glu-657” and “Glu-705”, reduces STAT1 phosphorylation and inhibits the production of pro-inflammatory cytokines in macrophages following IFNG stimulation. PARP14 Protein, Human (His, Strep) is the recombinant human-derived PARP14 protein, expressed by E. coli , with N-Strep, N-8*His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Transferases (EC 2)

/
HY-P701953 PARP15 Protein, Human (His)
PARP15 protein, acting as a mono-ADP-ribosyltransferase, facilitates the mono-ADP-ribosylation of target proteins. It also functions as a transcriptional negative regulator, impacting cellular processes and gene expression. PARP15 Protein, Human (His) is the recombinant human-derived PARP15 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Transferases (EC 2)

/
HY-P702868 PARP6 Protein, Human (sf9, His-GST)
PARP6 protein, a mono-ADP-ribosyltransferase, specializes in mediating the mono-ADP-ribosylation of target proteins. PARP6 Protein, Human (sf9, His-GST) is the recombinant human-derived PARP6 protein, expressed by Sf9 insect cells , with His-GST labeled tag.

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Transferases (EC 2)

/
HY-P704862 ROR1 Protein, Human (HEK293, mFc)
ROR1 protein's minimal kinase activity in vitro suggests an improbable role as a tyrosine kinase in vivo. It serves as a receptor for WNT5A, activating NFkB signaling and potentially inhibiting WNT3A signaling. Notably, ROR1 plays a vital role in the inner ear, facilitating innervation of auditory hair cells by spiral ganglion neurons. ROR1, Human (HEK293, mFc) is the recombinant human-derived ROR1 protein, expressed by HEK293, with C-mFc labeled tag.

Species: Human; Source: HEK293

Receptor Proteins Enzymes & Regulators Receptor Tyrosine Kinases Protein Tyrosine Kinases ROR family

/
HY-P704871 ROR1 Protein, Human (HEK293, Fc)
ROR1 protein's minimal kinase activity in vitro suggests an improbable role as a tyrosine kinase in vivo. It serves as a receptor for WNT5A, activating NFkB signaling and potentially inhibiting WNT3A signaling. Notably, ROR1 plays a vital role in the inner ear, facilitating innervation of auditory hair cells by spiral ganglion neurons. ROR1, Human (HEK293, Fc) is the recombinant human-derived ROR1 protein, expressed by HEK293, with C-mFc labeled tag.

Species: Human; Source: HEK293

Receptor Proteins Enzymes & Regulators Receptor Tyrosine Kinases Protein Tyrosine Kinases ROR family

/
HY-P705877 ROR1 Protein, Human (sf9)
ROR1 protein's minimal kinase activity in vitro suggests an improbable role as a tyrosine kinase in vivo. It serves as a receptor for WNT5A, activating NFkB signaling and potentially inhibiting WNT3A signaling. Notably, ROR1 plays a vital role in the inner ear, facilitating innervation of auditory hair cells by spiral ganglion neurons. ROR1, Human (sf9) is the recombinant human-derived ROR1 protein, expressed by sf9 insect cells, with N-Avi labeled tag.

Species: Human; Source: sf9 insect cells

CAR-T Related Proteins Receptor Proteins Enzymes & Regulators Kinases ROR1 Receptor Tyrosine Kinases Protein Tyrosine Kinases Pseudokinases TK ROR family Ror

/
HY-P706015 ROR1 Protein, Human (Active, sf9, His-GST)

Species: Human; Source: Sf9 insect cells

Kinases

/
HY-P80273 PD-L1 Antibody (YA235)
PD-L1 Antibody (YA235) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P87006 PD-L1 Antibody (YA6699)
PD-L1 Antibody (YA6699) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

Host: Rabbit; Reactivity: Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80265 PARP2 Antibody (YA244)
PARP2 Antibody (YA244) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PARP2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P87903 Cleaved PARP1 Antibody (YA7588)
Cleaved PARP1 Antibody (YA7588) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Cleaved PARP1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P88031 PARP2 Antibody (YA7716)
PARP2 Antibody (YA7716) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PARP2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86684 PD-L1 Antibody (YA6376)
PD-L1 Antibody (YA6376) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81741 ROR1 Antibody (YA1486)
ROR1 Antibody (YA1486) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ROR1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P87124 Tankyrase 2 Antibody (YA6817)
Tankyrase 2 Antibody (YA6817) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Tankyrase 2.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P87703 BRD4 Antibody (YA7388)
BRD4 Antibody (YA7388) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to BRD4.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80976A BRD4 Antibody (YA3486)(PBS only)
BRD4 Antibody (YA3486) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRD4.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P84465 ROR1 Antibody (YA4162)
ROR1 Antibody (YA4162) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to ROR1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P811793 PARP 4 Antibody (YA10264)
PARP 4 Antibody (YA10264) is a Rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to PARP 4.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P811793A PARP 4 Antibody (YA10264) (PBS only)
PARP 4 Antibody (YA10264) is a Rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to PARP 4.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84465A ROR1 Antibody (YA4162)(PBS only)
ROR1 Antibody (YA4162) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to ROR1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84842A PD-L1 Antibody (YA4539)(PBS only)
PD-L1 Antibody (YA4539) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P86751A PD-L1 Antibody (YA6443)(PBS only)
PD-L1 Antibody (YA6443) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P8F048A FITC-conjugated CD274 (PD-L1) Antibody (29E.2A3)
FITC-conjugated CD274 (PD-L1) Antibody (29E.2A3) is a Mouse-derived and FITC conjugated monoclonal antibody, targeting to CD274 (PD-L1).

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F048C PE-conjugated CD274 (PD-L1) Antibody (29E.2A3)
PE-conjugated CD274 (PD-L1) Antibody (29E.2A3) is a Mouse-derived and PE conjugated monoclonal antibody, targeting to CD274 (PD-L1).

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P84036 PARP1 Antibody (YA3733)
PARP1 Antibody (YA3733) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PARP1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84036A PARP1 Antibody (YA3733)(PBS only)
PARP1 Antibody (YA3733) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PARP1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84842 PD-L1 Antibody (YA4539)
PD-L1 Antibody (YA4539) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86751 PD-L1 Antibody (YA6443)
PD-L1 Antibody (YA6443) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-K0606 Methenamine Silver Stain Kit For Basement Membrane (PASM)

MCE Methenamine Silver Stain Kit For Basement Membrane (PASM) is developed based on the classical staining principle. Through an optimized staining system and standardized reagent combination, it enables clear visualization of basement membranes and related reticular structures in tissue sections. This method is particularly widely used in renal pathology research, where it is commonly applied to examine morphological alterations of the glomerular capillary basement membrane, such as thickening, rupture, folding, double-contour (tram-track) appearance, or abnormal proliferation caused by inflammatory injury. In addition, this method can also be applied to the histological investigation and morphological observation of glomerular diseases, diabetic nephropathy, and other basement membrane–associated pathological changes.

Cell Biology Cell Analysis Staining Kit

/
HY-K1043A Polyamine Supplement (1000×)

MCE Polyamine Supplement (1000×) can be used as a component of the CEPT Cocktail in combination with Emricasan, Chroman 1, and trans-ISRIB to enhance the survival of pluripotent stem cells (PSCs) and promote single-cell clonal expansion. In addition, this supplement improves the viability of PSCs and their differentiated derivatives during cryopreservation, organoid culture, single-cell cloning, and genome editing, thereby enhancing the robustness and reproducibility of downstream applications.

Cell Biology Cell Culture CEPT cocktail

/
HY-K3121 Bacterial Membrane Vesicle Isolation and Purification Kit

MCE Bacterial Membrane Vesicle Isolation and Purification Kit has been optimized specifically for the isolation and purification of bacterial membrane vesicles. The optimized formulation and purification workflow enable the isolation and purification of bacterial membrane vesicles from bacterial culture supernatants. In combination with an exosome purification column, the kit enables rapid and efficient enrichment of bacterial membrane vesicles, yielding vesicle particles with high purity and preserved structural integrity.

Cell Biology Cell Analysis Exosome Isolation, Purification and Detection

/
HY-KD1001 Vari Fluor 3-colour Multiple Fluorescent Staining Kit (For mouse samples)

The MCE three-color immunohistochemical kit marks the dual indicators. The kit contains rabbit secondary antibodies and can be used in combination with rabbit primary antibodies

Protein Biology Multiple Fluorescent Staining

/
HY-KD1003 Vari Fluor 4-colour Multiple Fluorescent Staining Kit (For mouse samples)

The MCE four-color immunohistochemical kit can label three indicators. The kit contains rabbit secondary antibodies and can be used in combination with rabbit primary antibodies.

Protein Biology

/
HY-KD1004 Vari Fluor 4-colour Multiple Fluorescent Staining Kit (For all samples)

The MCE four-color histochemical kit can label three indicators. The kit contains a universal secondary antibody for rabbits and mice and can be used in combination with primary antibodies for rabbits or mice.

Protein Biology Multiple Fluorescent Staining

/
HY-KD1004A Vari Fluor 4-colour Multiple Fluorescent Staining Kit-1 (For all samples)
Multiplex immunohistochemistry is also known as Tyramide Signal Amplification (TSA, Tyramide dignal amplification). It has been used for more than 20 years as an enzymatic assay for high-density in situ labelling of target proteins or nucleic acids by horseradish peroxidase (HRP). The method is based on multiple cis-immunostaining with tyramide signal amplification, which allows the detection of multiple target sites in cell or tissue samples in situ, and elucidation of their interaction mechanism through the study of the combination and positional relationship of these target sites.

Protein Biology Multiple Fluorescent Staining

/

References

[1]. Dawson MA, et al. Targeting epigenetic readers in cancer. N Engl J Med. 2012;367(7):647-657.  [Content Brief]

[2]. Jain AK, et al. Bromodomain histone readers and cancer. J Mol Biol. 2017;429(13):2003-2010.  [Content Brief]

[3]. Guo M, et al. Epigenetic heterogeneity in cancer. Biomark Res. 2019;7:23.  [Content Brief]

[4]. Fisher ML, et al. BRD4 regulates transcription factor ΔNp63α to drive a cancer stem cell phenotype in squamous cell carcinomas. Cancer Res. 2021;81(24):6246-6258.  [Content Brief]

[5]. Yamazaki M, et al. YAP/BRD4-controlled ROR1 promotes tumor-initiating cells and hyperproliferation in pancreatic cancer. EMBO J. 2023;42(14):e112614.  [Content Brief]

[6]. Zhu H, et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 2016;16(11):2829-2837.  [Content Brief]

[7]. Stathis A, et al. BET proteins as targets for anticancer treatment. Cancer Discov. 2018;8(1):24-36.  [Content Brief]

[8]. Sahai V, et al. Targeting BET bromodomain proteins in solid tumors. Oncotarget. 2016;7(33):53997-54009.  [Content Brief]

[9]. Karakashev S, et al. BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer. Cell Rep. 2017;21(12):3398-3405.  [Content Brief]

[10]. Shapiro GI, et al. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer. 2021;124(4):744-753.  [Content Brief]

Keywords

epigenetic reader proteins | tumor heterogeneity | BRD4 | BET inhibitors | chromatin regulation | cancer stemness | PD-L1 | ROR1 | PARP inhibitor combination therapy